var title_f27_35_28208="Accuracy of US in Crohns disease";
var content_f27_35_28208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity and specificity of ultrasonography in the detection of Crohn's disease (with respect to endoscopic, radiologic and operative findings)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"8\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity",
"       </td>",
"       <td class=\"subtitle1\">",
"        PPV",
"       </td>",
"       <td class=\"subtitle1\">",
"        NPV",
"       </td>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        181 (89)",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"       <td class=\"centered\">",
"        79",
"       </td>",
"       <td class=\"centered\">",
"        79",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"       <td class=\"centered\">",
"        [1]",
"       </td>",
"       <td class=\"centered\">",
"        Pera A, et al",
"       </td>",
"       <td class=\"centered\">",
"        1988",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        61 (26)",
"       </td>",
"       <td class=\"centered\">",
"        77",
"       </td>",
"       <td class=\"centered\">",
"        96",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [2]",
"       </td>",
"       <td class=\"centered\">",
"        Stiatti A, et al",
"       </td>",
"       <td class=\"centered\">",
"        1990",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        36",
"       </td>",
"       <td class=\"centered\">",
"        86",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [3]",
"       </td>",
"       <td class=\"centered\">",
"        Hata J, et al",
"       </td>",
"       <td class=\"centered\">",
"        1992",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        127 (46)",
"       </td>",
"       <td class=\"centered\">",
"        78 (87)*",
"       </td>",
"       <td class=\"centered\">",
"        91",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [4]",
"       </td>",
"       <td class=\"centered\">",
"        Sheridan MB, et al",
"       </td>",
"       <td class=\"centered\">",
"        1993",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        (31)",
"       </td>",
"       <td class=\"centered\">",
"        73",
"       </td>",
"       <td class=\"centered\">",
"        93",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [5]",
"       </td>",
"       <td class=\"centered\">",
"        Brignola C, et al",
"       </td>",
"       <td class=\"centered\">",
"        1993",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        41",
"       </td>",
"       <td class=\"centered\">",
"        96",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [6]",
"       </td>",
"       <td class=\"centered\">",
"        Limberg B, et al",
"       </td>",
"       <td class=\"centered\">",
"        1994",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        59",
"       </td>",
"       <td class=\"centered\">",
"        95",
"       </td>",
"       <td class=\"centered\">",
"        93",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        95",
"       </td>",
"       <td class=\"centered\">",
"        [7]",
"       </td>",
"       <td class=\"centered\">",
"        Solvig J, et al",
"       </td>",
"       <td class=\"centered\">",
"        1995",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        (115)",
"       </td>",
"       <td class=\"centered\">",
"        89",
"       </td>",
"       <td class=\"centered\">",
"        94",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [8]",
"       </td>",
"       <td class=\"centered\">",
"        Maconi G, et al",
"       </td>",
"       <td class=\"centered\">",
"        1996",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        227 (69)",
"       </td>",
"       <td class=\"centered\">",
"        84",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        98",
"       </td>",
"       <td class=\"centered\">",
"        76",
"       </td>",
"       <td class=\"centered\">",
"        [9]",
"       </td>",
"       <td class=\"centered\">",
"        Hollerbach S, et al",
"       </td>",
"       <td class=\"centered\">",
"        1998",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        (47)",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"       <td class=\"centered\">",
"        86",
"       </td>",
"       <td class=\"centered\">",
"        96",
"       </td>",
"       <td class=\"centered\">",
"        57",
"       </td>",
"       <td class=\"centered\">",
"        [10]",
"       </td>",
"       <td class=\"centered\">",
"        Andreoli A, et al",
"       </td>",
"       <td class=\"centered\">",
"        1998",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        30",
"       </td>",
"       <td class=\"centered\">",
"        87",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [11]",
"       </td>",
"       <td class=\"centered\">",
"        Miao YM, et al",
"       </td>",
"       <td class=\"centered\">",
"        2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        296",
"       </td>",
"       <td class=\"centered\">",
"        93",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [12]",
"       </td>",
"       <td class=\"centered\">",
"        Parente F, et al",
"       </td>",
"       <td class=\"centered\">",
"        2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        296 (211)",
"       </td>",
"       <td class=\"centered\">",
"        79",
"       </td>",
"       <td class=\"centered\">",
"        98",
"       </td>",
"       <td class=\"centered\">",
"        95",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [12]",
"       </td>",
"       <td class=\"centered\">",
"        Parente F, et al",
"       </td>",
"       <td class=\"centered\">",
"        2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        296 (85)",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [12]",
"       </td>",
"       <td class=\"centered\">",
"        Parente F, et al",
"       </td>",
"       <td class=\"centered\">",
"        2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        46",
"       </td>",
"       <td class=\"centered\">",
"        76",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [13]",
"       </td>",
"       <td class=\"centered\">",
"        Potthast S, et al",
"       </td>",
"       <td class=\"centered\">",
"        2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        46",
"       </td>",
"       <td class=\"centered\">",
"        31",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [13]",
"       </td>",
"       <td class=\"centered\">",
"        Potthast S, et al",
"       </td>",
"       <td class=\"centered\">",
"        2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        46",
"       </td>",
"       <td class=\"centered\">",
"        58",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [13]",
"       </td>",
"       <td class=\"centered\">",
"        Potthast S, et al",
"       </td>",
"       <td class=\"centered\">",
"        2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        46",
"       </td>",
"       <td class=\"centered\">",
"        89",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [13]",
"       </td>",
"       <td class=\"centered\">",
"        Potthast S, et al",
"       </td>",
"       <td class=\"centered\">",
"        2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        78",
"       </td>",
"       <td class=\"centered\">",
"        77",
"       </td>",
"       <td class=\"centered\">",
"        83",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [14]",
"       </td>",
"       <td class=\"centered\">",
"        Haber HP, et al",
"       </td>",
"       <td class=\"centered\">",
"        2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        48",
"       </td>",
"       <td class=\"centered\">",
"        56",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [15]",
"       </td>",
"       <td class=\"centered\">",
"        Schmidt T, et al",
"       </td>",
"       <td class=\"centered\">",
"        2003",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        48",
"       </td>",
"       <td class=\"centered\">",
"        56",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [15]",
"       </td>",
"       <td class=\"centered\">",
"        Schmidt T, et al",
"       </td>",
"       <td class=\"centered\">",
"        2003",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        48",
"       </td>",
"       <td class=\"centered\">",
"        67",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [15]",
"       </td>",
"       <td class=\"centered\">",
"        Schmidt T, et al",
"       </td>",
"       <td class=\"centered\">",
"        2003",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        625 (128)",
"       </td>",
"       <td class=\"centered\">",
"        87",
"       </td>",
"       <td class=\"centered\">",
"        96",
"       </td>",
"       <td class=\"centered\">",
"        93",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"       <td class=\"centered\">",
"        [16]",
"       </td>",
"       <td class=\"centered\">",
"        Maconi G, et al",
"       </td>",
"       <td class=\"centered\">",
"        2003",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        625 (128)",
"       </td>",
"       <td class=\"centered\">",
"        91",
"       </td>",
"       <td class=\"centered\">",
"        85",
"       </td>",
"       <td class=\"centered\">",
"        77",
"       </td>",
"       <td class=\"centered\">",
"        94",
"       </td>",
"       <td class=\"centered\">",
"        [16]",
"       </td>",
"       <td class=\"centered\">",
"        Maconi G, et al",
"       </td>",
"       <td class=\"centered\">",
"        2003",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        102",
"       </td>",
"       <td class=\"centered\">",
"        91/96",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [17]",
"       </td>",
"       <td class=\"centered\">",
"        Parente F, et al",
"       </td>",
"       <td class=\"centered\">",
"        2004",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        102",
"       </td>",
"       <td class=\"centered\">",
"        74/89",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        92",
"       </td>",
"       <td class=\"centered\">",
"        96",
"       </td>",
"       <td class=\"centered\">",
"        [17]",
"       </td>",
"       <td class=\"centered\">",
"        Parente F, et al",
"       </td>",
"       <td class=\"centered\">",
"        2004",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        84 (50)",
"       </td>",
"       <td class=\"centered\">",
"        92",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"       <td class=\"centered\">",
"        98",
"       </td>",
"       <td class=\"centered\">",
"        88",
"       </td>",
"       <td class=\"centered\">",
"        [18]",
"       </td>",
"       <td class=\"centered\">",
"        Rispo A, et al",
"       </td>",
"       <td class=\"centered\">",
"        2005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        48",
"       </td>",
"       <td class=\"centered\">",
"        81",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        63",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        63",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        81",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        [19]",
"       </td>",
"       <td class=\"centered\">",
"        Serra C, et al",
"       </td>",
"       <td class=\"centered\">",
"        2007",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        53",
"       </td>",
"       <td class=\"centered\">",
"        85",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [20]",
"       </td>",
"       <td class=\"centered\">",
"        Maconi G, et al",
"       </td>",
"       <td class=\"centered\">",
"        2007",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        119",
"       </td>",
"       <td class=\"centered\">",
"        91",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [21]",
"       </td>",
"       <td class=\"centered\">",
"        Martinez MJ, et al",
"       </td>",
"       <td class=\"centered\">",
"        2009",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        119",
"       </td>",
"       <td class=\"centered\">",
"        80",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        NE",
"       </td>",
"       <td class=\"centered\">",
"        [21]",
"       </td>",
"       <td class=\"centered\">",
"        Martinez MJ, et al",
"       </td>",
"       <td class=\"centered\">",
"        2009",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        58",
"       </td>",
"       <td class=\"centered\">",
"        86",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        83",
"       </td>",
"       <td class=\"centered\">",
"        92",
"       </td>",
"       <td class=\"centered\">",
"        [22]",
"       </td>",
"       <td class=\"centered\">",
"        Neye H, et al",
"       </td>",
"       <td class=\"centered\">",
"        2010",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        58",
"       </td>",
"       <td class=\"centered\">",
"        78",
"       </td>",
"       <td class=\"centered\">",
"        95",
"       </td>",
"       <td class=\"centered\">",
"        86",
"       </td>",
"       <td class=\"centered\">",
"        91",
"       </td>",
"       <td class=\"centered\">",
"        [22]",
"       </td>",
"       <td class=\"centered\">",
"        Neye H, et al",
"       </td>",
"       <td class=\"centered\">",
"        2010",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        58",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"       <td class=\"centered\">",
"        [22]",
"       </td>",
"       <td class=\"centered\">",
"        Neye H, et al",
"       </td>",
"       <td class=\"centered\">",
"        2010",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PPV: positive predictive value; NPV: negative predictive value; NE: not evaluable. Parentheses indicate the number of patients with proven Crohn's disease, if noted.",
"     <br>",
"      * Learning curve.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Oral contrast-enhanced ultrasound.",
"       <br>",
"        &Delta; Contrast-enhanced ultrasound.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         Transperineal ultrasound.",
"         <br/>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Pera A, Cammarota T, Comino E, Caldera D, Ponti V, Astegiano M et al. Ultrasonography in the detection of Crohn's disease and in the differential diagnosis of inflammatory bowel disease. Digestion 1988; 41:180.",
"      </li>",
"      <li>",
"       Stiatti A, Martinuzzi A, Bartolini M, Lascialfari L, Trallori G, Morettini A. Ultrasonography in the diagnosis of chronic inflammatory intestinal disease. Radiol Med (Torino) 1990; 80:301.",
"      </li>",
"      <li>",
"       Hata J, Haruma K, Suenaga K, Yoshihara M, Yamamoto G, Tanaka S et al. Ultrasonographic assessment of inflammatory bowel disease. Am J Gastroenterol 1992; 87:443.",
"      </li>",
"      <li>",
"       Sheridan MB, Nicholson DA, Martin DF. Transabdominal ultrasonography as the primary investigation in patients with suspected Crohn's disease or recurrence: a prospective study. Clin Radiol 1993; 48:402.",
"      </li>",
"      <li>",
"       Brignola C, Belloli C, Iannone P, De Simone G, Corbelli C, Levorato M et al. Comparison of scintigraphy with indium-111 leukocyte scan and ultrasonography in assessment of X-ray-demonstrated lesions of Crohn's disease. Dig Dis Sci 1993; 38:433.",
"      </li>",
"      <li>",
"       Limberg B, Osswald B. Diagnosis and differential diagnosis of ulcerative colitis and Crohn's disease by hydrocolonic sonography. Am J Gastroenterol 1994; 89:1051.",
"      </li>",
"      <li>",
"       Solvig J, Ekberg O, Lindgren S, Floren CH, Nilsson P. Ultrasound examination of the small bowel: comparison with enteroclysis in patients with Crohn disease. Abdom Imaging 1995; 20:323.",
"      </li>",
"      <li>",
"       Maconi G, Parente F, Bollani S, Cesana B, Bianchi PG. Abdominal ultrasound in the assessment of extent and activity of Crohn's disease: clinical significance and implication of bowel wall thickening. Am J Gastroenterol 1996; 91:1604.",
"      </li>",
"      <li>",
"       Hollerbach S, Geissler A, Schiegl H, Kullmann F, Lock G, Schmidt J et al. The accuracy of abdominal ultrasound in the assessment of bowel disorders. Scand J Gastroenterol 1998; 33:1201.",
"      </li>",
"      <li>",
"       Andreoli A, Cerro P, Falasco G, Giglio LA, Prantera C. Role of ultrasonography in the diagnosis of postsurgical recurrence of Crohn's disease. Am J Gastroenterol 1998; 93:1117.",
"      </li>",
"      <li>",
"       Miao YM, Koh DM, Amin Z, Healy JC, Chinn RJ, Zeegen R et al. Ultrasound and magnetic resonance imaging assessmentof active bowel segments in Crohn's disease. Clin Radiol 2002; 57:913.",
"      </li>",
"      <li>",
"       Parente F, Maconi G, Bollani S, Anderloni A, Sampietro G, Cristaldi M et al. Bowel ultrasound in assessment of Crohn's disease and detection of related small bowel strictures: a prospective comparative study versus x ray and intraoperative findings. Gut 2002; 50:490.",
"      </li>",
"      <li>",
"       Potthast S, Rieber A, Von Tirpitz C, Wruk D, Adler G, Brambs HJ. Ultrasound and magnetic resonance imaging in Crohn's disease: a comparison. Eur Radiol 2002; 12:1416.",
"      </li>",
"      <li>",
"       Haber HP, Busch A, Ziebach R, Dette S, Ruck P, Stern M. Ultrasonographic findings correspond to clinical, endoscopic, and histologic findings in inflammatory bowel disease and other enterocolitides. J Ultrasound Med 2002; 21:375.",
"      </li>",
"      <li>",
"       Schmidt T, Reinshagen M, Brambs HJ, Adler G, Rieber A, Tirpitz V et al. Comparison of conventional enteroclysis, intestinal ultrasound and MRI-enteroclysis for determining changes in the small intestine and complications in patients with Crohn's disease. Z Gastroenterol 2003; 41:641.",
"      </li>",
"      <li>",
"       Maconi G, Sampietro GM, Parente F, Pompili G, Russo A, Cristaldi M et al. Contrast radiology, computed tomography and ultrasonography in detecting internal fistulas and intra-abdominal abscesses in Crohn's disease: a prospective comparative study. Am J Gastroenterol 2003; 98:1545.",
"      </li>",
"      <li>",
"       Parente F, Greco S, Molteni M, Anderloni A, Sampietro GM, Danelli PG et al. Oral contrast enhanced bowel ultrasonography in the assessment of small intestine Crohn's disease. A prospective comparison with conventional ultrasound, x ray studies, and ileocolonoscopy. Gut 2004; 53:1652.",
"      </li>",
"      <li>",
"       Rispo A, Imbriaco M, Celentano L, Cozzolino A, Camera L, Mainenti PP et al. Noninvasive diagnosis of small bowel Crohn's disease: combined use of bowel sonography and Tc-99m-HMPAO leukocyte scintigraphy. Inflamm Bowel Dis 2005; 11:376.",
"      </li>",
"      <li>",
"       Serra C, Menozzi G, Labate AM, Giangregorio F, Gionchetti P, Beltrami M, Robotti D, Fornari F, Cammarota T. Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn's disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent. Eur J Radiol. 2007; 62:114.",
"      </li>",
"      <li>",
"       Maconi G, Ardizzone S, Greco S, Radice E, Bezzio C, Bianchi Porro G. Transperineal ultrasound in the detection of perianal and rectovaginal fistulae in Crohn's disease. Am J Gastroenterol. 2007; 102:2214.",
"      </li>",
"      <li>",
"       Mart&iacute;nez MJ, Ripoll&eacute;s T, Paredes JM, Blanc E, Mart&iacute;-Bonmat&iacute; L. Assessment of the extension and the inflammatory activity in Crohn's disease: comparison of ultrasound and MRI. Abdom Imaging. 2009; 34:141.",
"      </li>",
"      <li>",
"       Neye H, Ensberg D, Rauh P, Peitz U, M&ouml;nkem&uuml;ller K, Treiber G, Klauck S, Malfertheiner P, Rickes S.Impact of high-resolution transabdominal ultrasound in the diagnosis of complications of Crohn's disease. Scand J Gastroenterol. 2010; 45: 690.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28208=[""].join("\n");
var outline_f27_35_28208=null;
var title_f27_35_28209="Budding of yeast phase";
var content_f27_35_28209=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blastomyces dermatitidis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Section of yeast phase of Blastomyces dermatitidis in tissue shows a thick cell with reproduction via a single, large, broad-based bud.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley W Chapman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28209=[""].join("\n");
var outline_f27_35_28209=null;
var title_f27_35_28210="Egg donor synchronization schedule";
var content_f27_35_28210=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Synchronization schedule between an egg donor and female recipient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic figure demonstrating a typical synchronization schedule between an egg donor and the female recipient. Cleavage stage embryos are transferred on day 3 and blastocysts on day 5 post-fertilization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28210=[""].join("\n");
var outline_f27_35_28210=null;
var title_f27_35_28211="Cholesterol crystals";
var content_f27_35_28211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Gallbladder bile microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholesterol crystals on microscopy. Note the rhomboid appearance with the notch on one corner.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Salam F Zakko, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28211=[""].join("\n");
var outline_f27_35_28211=null;
var title_f27_35_28212="Patient information: Chronic kidney disease (The Basics)";
var content_f27_35_28212=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15405\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"         Anatomy of the urinary tract",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/17/24850\">",
"         Patient information: Bone problems caused by kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/42/19107\">",
"         Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/2/18467\">",
"         Patient information: Dialysis and diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/31/37363\">",
"         Patient information: Glomerular disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/1/25619\">",
"         Patient information: Hemodialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/46/25315\">",
"         Patient information: Kidney transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/33/8722\">",
"         Patient information: Low-potassium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/49/36626\">",
"         Patient information: Lupus and kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/62/9188\">",
"         Patient information: Medicines for chronic kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/43/16051\">",
"         Patient information: Peritoneal dialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/15/12531\">",
"         Patient information: Planning for a kidney transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/22/11619\">",
"         Patient information: Preparing for hemodialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/43/692\">",
"         Patient information: Type 1 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/5/13398\">",
"         Patient information: Chronic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/26/9635\">",
"         Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/53/32594\">",
"         Patient information: Edema (swelling) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/35/37426\">",
"         Patient information: Glomerular disease overview (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/57/40852\">",
"         Patient information: Hemodialysis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/41/42640\">",
"         Patient information: Low potassium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/61/39890\">",
"         Patient information: Low sodium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/10/14501\">",
"         Patient information: Peritoneal dialysis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/24/38277\">",
"         Patient information: Polycystic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/35/15921\">",
"         Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/14/30944\">",
"         Patient information: Renal (kidney) biopsy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/7/28799\">",
"         Patient information: Split urine collection for orthostatic proteinuria (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/2/35875\">",
"         Patient information: The nephrotic syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chronic kidney disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chronic-kidney-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H34818394\">",
"      <span class=\"h1\">",
"       What is chronic kidney disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chronic kidney disease is when the kidneys stop working as well as they should. When they are working normally, the kidneys filter the blood and remove waste and excess salt and water (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      In people with chronic kidney disease, the kidneys slowly lose the ability to filter the blood. In time, the kidneys can stop working completely. That is why it is so important to keep chronic kidney disease from getting worse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34818401\">",
"      <span class=\"h1\">",
"       What are the symptoms of chronic kidney disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;At first, chronic kidney disease causes no symptoms. As the disease gets worse, it can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Make your feet, ankles, or legs swell (doctors call this &ldquo;edema&rdquo;)",
"       </li>",
"       <li>",
"        Give you high blood pressure",
"       </li>",
"       <li>",
"        Make you very tired",
"       </li>",
"       <li>",
"        Damage your bones",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34818408\">",
"      <span class=\"h1\">",
"       Is there anything I can do to keep my kidneys from getting worse if I have chronic kidney disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, you can protect your kidneys by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Taking blood pressure and other medicines every day, if your doctor or nurse prescribes them to you",
"       </li>",
"       <li>",
"        Keeping your blood sugar in a healthy range, if you have diabetes",
"       </li>",
"       <li>",
"        Changing your diet, if your doctor or nurse says you should",
"       </li>",
"       <li>",
"        Avoiding medicines known as &ldquo;nonsteroidal antiinflammatory drugs,&rdquo; or NSAIDs. These medicines include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sold as Advil&reg; or Motrin&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sold as Aleve&reg;). Check with your doctor, nurse, or kidney specialist before starting any new medicines &mdash; even over-the-counter ones.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34818415\">",
"      <span class=\"h1\">",
"       What are the treatments for chronic kidney disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People in the early stages of chronic kidney disease can take medicines to keep the disease from getting worse. For example, many people with chronic kidney disease should take medicines known as &ldquo;ACE inhibitors&rdquo; or &ldquo;angiotensin receptor blockers.&rdquo; If your doctor or nurse prescribes these medicines, it is very important that you take them every day as directed. If they cause side effects or cost too much, speak to your doctor or nurse about it. He or she might have solutions to offer. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34818422\">",
"      <span class=\"h1\">",
"       What happens if my kidneys stop working completely?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your kidneys stop working completely, you can choose between three different treatments to take over the job of your kidneys. Your choices are described below.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        You can have kidney transplant surgery. That way, the new kidney can do the job of your own kidneys. If you have a kidney transplant, you will need to take medicines for the rest of your life to keep your body from reacting badly to the new kidney. (You only need one kidney to live.)",
"       </li>",
"       <li>",
"        You can have your blood filtered by a machine. This treatment is called &ldquo;hemodialysis,&rdquo; but many people call it just &ldquo;dialysis.&rdquo; If you choose this approach, you will need to be hooked up to the machine at least 3 times a week for a few hours for the rest of your life. Before you start, you will also need to have surgery to prepare a blood vessel for attachment to the machine.",
"       </li>",
"       <li>",
"        You can learn to use a special fluid that has to be piped in and out of your belly every day. This treatment is called &ldquo;peritoneal dialysis.&rdquo; If you choose this type of dialysis, you will need surgery to have a tube implanted in your belly. Then you will have to learn how to pipe the fluid in and out through that tube.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34818429\">",
"      <span class=\"h1\">",
"       How do I choose between the different treatment options?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You and your doctor will need to work together to find a treatment that's right for you. Kidney transplant surgery is usually the best option for most people. But often there are no kidneys available for transplant.",
"     </p>",
"     <p>",
"      Ask your doctor to explain all of your options and how they might work for you. Then talk openly with him or her about how you feel about all of the options. You may even decide that you do not want any treatment. That is your choice.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34818436\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       Patient information: Type 1 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=see_link\">",
"       Patient information: Hemodialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=see_link\">",
"       Patient information: Peritoneal dialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=see_link\">",
"       Patient information: Preparing for hemodialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=see_link\">",
"       Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/2/18467?source=see_link\">",
"       Patient information: Dialysis and diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=see_link\">",
"       Patient information: Kidney transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=see_link\">",
"       Patient information: Planning for a kidney transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/31/37363?source=see_link\">",
"       Patient information: Glomerular disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/33/8722?source=see_link\">",
"       Patient information: Low-potassium diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/17/24850?source=see_link\">",
"       Patient information: Bone problems caused by kidney disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/49/36626?source=see_link\">",
"       Patient information: Lupus and kidney disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/62/9188?source=see_link\">",
"       Patient information: Medicines for chronic kidney disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"       Patient information: Chronic kidney disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"       Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=see_link\">",
"       Patient information: Edema (swelling) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=see_link\">",
"       Patient information: Glomerular disease overview (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       Patient information: Hemodialysis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42640?source=see_link\">",
"       Patient information: Low potassium diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"       Patient information: Low sodium diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"       Patient information: Peritoneal dialysis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/24/38277?source=see_link\">",
"       Patient information: Polycystic kidney disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=see_link\">",
"       Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/14/30944?source=see_link\">",
"       Patient information: Renal (kidney) biopsy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/7/28799?source=see_link\">",
"       Patient information: Split urine collection for orthostatic proteinuria (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/2/35875?source=see_link\">",
"       Patient information: The nephrotic syndrome (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/35/28212?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15405 Version 12.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28212=[""].join("\n");
var outline_f27_35_28212=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34818394\">",
"      What is chronic kidney disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34818401\">",
"      What are the symptoms of chronic kidney disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34818408\">",
"      Is there anything I can do to keep my kidneys from getting worse if I have chronic kidney disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34818415\">",
"      What are the treatments for chronic kidney disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34818422\">",
"      What happens if my kidneys stop working completely?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34818429\">",
"      How do I choose between the different treatment options?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34818436\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15405\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"      Anatomy of the urinary tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/17/24850?source=related_link\">",
"      Patient information: Bone problems caused by kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=related_link\">",
"      Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/2/18467?source=related_link\">",
"      Patient information: Dialysis and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=related_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/31/37363?source=related_link\">",
"      Patient information: Glomerular disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=related_link\">",
"      Patient information: Glomerular disease overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=related_link\">",
"      Patient information: Hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=related_link\">",
"      Patient information: Kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42640?source=related_link\">",
"      Patient information: Low potassium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/33/8722?source=related_link\">",
"      Patient information: Low-potassium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/49/36626?source=related_link\">",
"      Patient information: Lupus and kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/62/9188?source=related_link\">",
"      Patient information: Medicines for chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=related_link\">",
"      Patient information: Peritoneal dialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=related_link\">",
"      Patient information: Planning for a kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/24/38277?source=related_link\">",
"      Patient information: Polycystic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=related_link\">",
"      Patient information: Preparing for hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=related_link\">",
"      Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/14/30944?source=related_link\">",
"      Patient information: Renal (kidney) biopsy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/7/28799?source=related_link\">",
"      Patient information: Split urine collection for orthostatic proteinuria (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/2/35875?source=related_link\">",
"      Patient information: The nephrotic syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_35_28213="Povidone iodine (topical): Drug information";
var content_f27_35_28213=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Povidone iodine (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9505342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Betadine&reg; Swab Aids [OTC];",
"     </li>",
"     <li>",
"      Betadine&reg; [OTC];",
"     </li>",
"     <li>",
"      Operand&reg; Povidone-Iodine [OTC];",
"     </li>",
"     <li>",
"      Povidine&trade; [OTC];",
"     </li>",
"     <li>",
"      Summer's Eve&reg; Medicated Douche [OTC];",
"     </li>",
"     <li>",
"      Vagi-Gard&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9505343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Betadine&reg;;",
"     </li>",
"     <li>",
"      Proviodine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9509765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiseptic, Topical;",
"     </li>",
"     <li>",
"      Antiseptic, Vaginal;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9505462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiseptic:",
"     </b>",
"     Topical: Apply to affected area as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Surgical scrub:",
"     </b>",
"     Topical: Apply solution to wet skin or hands, scrub for ~5 minutes, rinse; refer to product labeling for specific procedure-related instructions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vaginal irritation:",
"     </b>",
"     Douche: Insert 0.3% solution vaginally once daily for 5-7 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9505463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9505491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 10% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Operand&reg; Povidone-Iodine: 10% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [prep swab ampule]: 10% (0.65 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 10% (1 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Povidine&trade;: 10% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pad, topical [prep pads]: 10% (200s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betadine&reg; Swab Aids: 10% (100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, perineal [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Operand&reg; Povidone-Iodine: 10% (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 10% (22 mL, 30 mL, 60 mL, 120 mL, 237 mL, 240 mL, 473 mL, 480 mL, 3840 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betadine&reg;: 10% (15 mL, 120 mL, 237 mL, 473 mL, 960 mL, 3840 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Operand&reg; Povidone-Iodine: 10% (59 mL, 118 mL, 237 mL, 473 mL, 946 mL, 3785 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Povidine&trade;: 10% (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [cleanser]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betadine&reg;: 7.5% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [concentrate/whirlpool]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Operand&reg; Povidone-Iodine: 10% (3785 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [paint]: 10% (60 mL, 90 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [paint sponge]: 10% (50s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [spray]: 10% (59 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betadine&reg;: 5% (88.7 mL) [chlorofluorocarbon free; contains natural rubber/natural latex in packaging]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [surgical scrub]: 7.5% (60 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betadine&reg;: 7.5% (118 mL, 473 mL, 960 mL, 3840 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Operand&reg; Povidone-Iodine: 7.5% (59 mL, 118 mL, 237 mL, 473 mL, 946 mL, 3785 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [surgical scrub sponge]: 10% (50s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, vaginal [concentrate, douche]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Operand&reg; Povidone-Iodine: 10% (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vagi-Gard&reg;: 10% (180 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, vaginal [douche]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Summer's Eve&reg; Medicated Douche: 0.3% (135 mL) [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Swabsticks, topical: 10% (1000s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betadine&reg;: 10% (150s, 200s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Swabsticks, topical [gel saturated]: 10% (50s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Swabsticks, topical [paint]: 10% (50s, 75s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Swabsticks, topical [surgical scrub]: 7.5% (50s, 75s, 1000s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9505373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9505374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     External antiseptic with broad microbicidal spectrum for the prevention or treatment of topical infections associated with surgery, burns, minor cuts/scrapes; relief of minor vaginal irritation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9505336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Betadine&reg; may be confused with Betagan&reg;, betaine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9505438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. Also refer to Iodine monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Edema, irritation, pruritus, rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9505380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iodine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9505383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Toxicity: May occur following application of large or prolonged quantities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Burns: Use with caution in patients with burns.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Do not apply to deep puncture wounds or serious burns; discontinue in case of redness, swelling, irritation or pain; do not use for longer than 1 week.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9505441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9505376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vaginal products should not be used during pregnancy. Absorbed systemically as iodine. Transient hypothyroidism in the newborn has been reported following topical or vaginal use prior to delivery. Refer to Iodine for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9505378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9505379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Iodine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Betadine Spray External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (88.7 mL): $11.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (One-Step Prep Povidone-Iodine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (110 mL): $1.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Operand Povidone-Iodine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (118 g): $2.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Iodex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.7% (28.35 g): $11.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Povidone-Iodine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (28.35 g): $3.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Betadine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (237 mL): $2.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Betadine Skin Cleanser External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5% (118 mL): $9.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Betadine Surgical Scrub External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5% (473 mL): $4.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Curity Povidone-Iodine Paint External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (89 mL): $1.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Curity Povidone-Iodine Scrub External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (89 mL): $1.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (GRX Dyne External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (237 mL): $3.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (GRX Dyne Scrub External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5% (118 mL): $1.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Operand Povidone-Iodine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (59 mL): $1.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Operand Povidone-Iodine Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (237 mL): $6.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Operand Scrub External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5% (473 mL): $4.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Povidone-Iodine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (237 mL): $4.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Summers Eve Disp Medicated Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3% (133 mL): $1.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (VH Essentials Medicated Douche Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (237 mL): $6.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Swab",
"     </b>",
"     (Betadine Swab Aid External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (100): $7.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Swab",
"     </b>",
"     (Betadine Swabsticks External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (1): $0.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Swab",
"     </b>",
"     (ExCel AP External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-72% (1): $53.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Swab",
"     </b>",
"     (Povidone-Iodine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5% (50): $13.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (50): $11.08",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abodine (PK);",
"     </li>",
"     <li>",
"      Alfadine (PH);",
"     </li>",
"     <li>",
"      Bacterodine (DO);",
"     </li>",
"     <li>",
"      Bactroderm (CO);",
"     </li>",
"     <li>",
"      Besetine (KP);",
"     </li>",
"     <li>",
"      Betadine (AU, BG, CH, CZ, FI, FR, GB, GR, HK, HN, IN, IT, MY, NL, NO, PH, PK, PT, SG, TH, VE, ZA);",
"     </li>",
"     <li>",
"      Betaisodona (AT, DE);",
"     </li>",
"     <li>",
"      Better-Iodine (TW);",
"     </li>",
"     <li>",
"      Biocil (NZ);",
"     </li>",
"     <li>",
"      Braunol (BE, BG, CH, DE);",
"     </li>",
"     <li>",
"      Braunosan (CH);",
"     </li>",
"     <li>",
"      Braunovidon (AT, EE);",
"     </li>",
"     <li>",
"      Difexon (CN);",
"     </li>",
"     <li>",
"      E.D.P. (AU);",
"     </li>",
"     <li>",
"      Favol (PY);",
"     </li>",
"     <li>",
"      Igiol (GR);",
"     </li>",
"     <li>",
"      Intradine (VE);",
"     </li>",
"     <li>",
"      Iodicare (IL);",
"     </li>",
"     <li>",
"      Iodo-Vit (IL);",
"     </li>",
"     <li>",
"      Iodofon (UY);",
"     </li>",
"     <li>",
"      Iop (PY);",
"     </li>",
"     <li>",
"      Isodine (CO, PE);",
"     </li>",
"     <li>",
"      Li Ze (CL);",
"     </li>",
"     <li>",
"      Marcodine (BR);",
"     </li>",
"     <li>",
"      Pharmadine (TH);",
"     </li>",
"     <li>",
"      Podine (ZA);",
"     </li>",
"     <li>",
"      Polydine (IL);",
"     </li>",
"     <li>",
"      Povibac (AR);",
"     </li>",
"     <li>",
"      Povidine (IN);",
"     </li>",
"     <li>",
"      Povidyne (EC);",
"     </li>",
"     <li>",
"      Sabofen (BR);",
"     </li>",
"     <li>",
"      Septadine (ID);",
"     </li>",
"     <li>",
"      Throane (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9505445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Povidone-iodine is known to be a powerful broad spectrum germicidal agent effective against a wide range of bacteria, viruses, fungi, protozoa, and spores.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9505446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Absorbed systemically as iodine; amount depends upon concentration, route of administration, characteristics of skin",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/35/28213/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dela Cruz F, Brown DH, Leikin JB, et al, &ldquo;Iodine Absorption After Topical Administration,&rdquo;",
"      <i>",
"       West J Med",
"      </i>",
"      , 1987, 146(1):43-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/35/28213/abstract-text/3825108/pubmed\" id=\"3825108\" target=\"_blank\">",
"        3825108",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9910 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28213=[""].join("\n");
var outline_f27_35_28213=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505342\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505343\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9509765\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505462\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505463\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505491\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505373\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505374\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505336\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505438\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505380\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505383\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299928\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505441\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505376\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505378\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505379\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322430\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962003\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505445\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505446\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9910\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9910|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29570?source=related_link\">",
"      Povidone iodine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_35_28214="Warthin Starry staining";
var content_f27_35_28214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Warthin-Starry staining in Bartonella infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The small black clusters represent Bartonella organisms that have taken up the Warthin-Starry stain (red arrows). The larger black staining material represents cell nuclei (blue arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David H Spach, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28214=[""].join("\n");
var outline_f27_35_28214=null;
var title_f27_35_28215="Chronic exertional compartment syndrome";
var content_f27_35_28215=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic exertional compartment syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/35/28215/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28215/contributors\">",
"     William P Meehan, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/35/28215/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28215/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/35/28215/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28215/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/35/28215/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H31749648\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;First described by Mavor in 1956 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/1\">",
"     1",
"    </a>",
"    ], chronic exertional compartment syndrome (CECS) is an overuse injury that typically affects young endurance athletes, especially those who run extensively. Like acute compartment syndrome, it is thought to result from increased pressure within the confines of the osteofascial planes of a muscle compartment. CECS occurs primarily in the lower leg, although it has been reported in the upper extremity and elsewhere in the body [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presentation, diagnosis, and management of chronic exertional compartment syndrome are reviewed here. Acute compartment syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31749655\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true prevalence of chronic exertional compartment syndrome (CECS) in the general population is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/3\">",
"     3",
"    </a>",
"    ]. It is likely that many people suffering from early symptoms of CECS decrease or modify their activity level to manage their condition and never seek medical attention. In addition, CECS is likely under-diagnosed by the coaches, athletic trainers, and primary care physicians to whom symptoms are first presented [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/4\">",
"     4",
"    </a>",
"    ]. The gold standard for diagnosis requires invasive pressure measurements in the affected muscle compartment, something rarely done in training rooms or primary care clinics.",
"   </p>",
"   <p>",
"    Small observational studies give a limited sense of the prevalence of CECS among certain populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 108 patients with lower leg pain of unknown cause, elevated intracompartmental pressures were found in 15 patients (13.9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 131 patients referred for chronic exertional leg pain, 45 patients (34 percent) were found to have CECS, as determined by elevated intracompartmental pressure measurements [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intracompartmental pressure measurements confirmed the diagnosis of CECS in 22 of 80 patients (28 percent) with recurrent exercise-induced pain in the anterior leg referred to a specialty clinic [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another observational study reported that 82 percent of patients referred for suspected CECS had elevated intracompartmental pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most published case reports of CECS describe the diagnosis in athletes, particularly runners, with vigorous training regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The highest percentage occurs in the lower leg [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/2\">",
"     2",
"    </a>",
"    ], most often in the anterior compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/4,8-10\">",
"     4,8-10",
"    </a>",
"    ]. However, cases of CECS in non-athletes and cases involving compartments of the foot, thigh, forearm, and hand have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Men and women are equally affected.",
"   </p>",
"   <p>",
"    It is difficult to draw conclusions about factors that contribute to CECS because the condition is often misdiagnosed initially and there may be a delay of months or even years between the onset of symptoms and definitive diagnosis. Anecdotal evidence suggests sudden increases in training volume may contribute, but such claims are susceptible to recall bias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31749662\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of chronic exertional compartment syndrome (CECS) is not completely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Exercise increases blood flow to active muscles causing them to expand. If constricted by surrounding noncompliant fascia, such swelling increases pressure within the muscle compartment. Ultimately, the increased pressure within the compartment reduces blood flow, leading to muscle ischemia and pain when metabolic demands cannot be met. Several studies have demonstrated decreased blood flow and oxygenation in the legs of symptomatic patients with CECS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/18-21\">",
"     18-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31749669\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical patient with chronic exertional compartment syndrome (CECS) is a young athlete, often a runner, who describes gradually increasing pain in a specific muscle region (usually the lower leg) during physical exertion (",
"    <a class=\"graphic graphic_figure graphicRef59437 \" href=\"UTD.htm?25/33/26137\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/3-5,7,10,16,22,23\">",
"     3-5,7,10,16,22,23",
"    </a>",
"    ]. The pain may be described as aching, squeezing, cramping, or tightness. Pain generally begins within several minutes of starting the inciting activity, often at a specific point in training that patients recognize. As an example, runners often can describe the time or distance required for symptoms to develop.",
"   </p>",
"   <p>",
"    Pain resolves completely with rest, although not immediately upon stopping exercise. Complete resolution of symptoms occurs shortly (10 to 20 minutes) after activity is stopped and is so characteristic that the diagnosis should be reconsidered if such a correlation cannot be established. However, acute-on-chronic compartment syndrome can develop, in which case pain does not resolve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Clinical features and diagnosis'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    CECS often occurs bilaterally. Neurologic symptoms such as paresthesias, numbness, and foot-drop can occur. The structures found in the muscle compartments of the upper and lower extremities, and the symptoms and signs associated with elevated pressures within these compartments, are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H7#H7\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Anatomic compartments and related clinical signs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 80 patients referred to a clinic for suspected CECS, researchers reported that compartment syndrome of the lower leg was more likely if [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pain was only induced by athletic activity.",
"     </li>",
"     <li>",
"      The pain was limited to the anterior compartment.",
"     </li>",
"     <li>",
"      The pain required the athlete to stop running.",
"     </li>",
"     <li>",
"      Tenderness was present nowhere else in the leg but the involved compartment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical examination of patients suffering from CECS is often unremarkable at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/3,10,16\">",
"     3,10,16",
"    </a>",
"    ]. It can be helpful to examine the patient after they exercise to the point of eliciting symptoms. The involved compartment may be tender. Relative weakness of muscles in the involved compartment may be noted when compared with a pre-exercise evaluation. Muscle hernias are frequently present, occurring in 20 to 60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/5-7,16,24\">",
"     5-7,16,24",
"    </a>",
"    ]. However, these are frequently seen in patients with other causes of lower leg pain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/6,7,22\">",
"     6,7,22",
"    </a>",
"    ]. Bulky, well-developed calf muscles may be noted [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. Abnormal distal pulses are uncommon in CECS and should lead the clinician to reconsider the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/3,5,10\">",
"     3,5,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H504249\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Researchers continue to investigate a number of non-invasive methods for diagnosing CECS in order to avoid the need for direct, invasive intramuscular pressure measurements. Prospective techniques include:",
"    <sup>",
"     31",
"    </sup>",
"    P-NMR spectroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/25\">",
"     25",
"    </a>",
"    ], MIBI perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/26\">",
"     26",
"    </a>",
"    ], magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/27\">",
"     27",
"    </a>",
"    ], and thallium-201 single photon emission tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, no noninvasive measurement technique has been accepted as an equivalent alternative to direct pressure measurement. Therefore, imaging should be considered only as a means of ruling out other potential etiologies. Bone scan and MRI may be used to look for stress fracture, stress reaction, or periostitis. Ultrasound or MRI may be used to assess for nerve or arterial entrapment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H502554\">",
"    <span class=\"h1\">",
"     COMPARTMENT PRESSURE MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the history and physical examination suggest the diagnosis of chronic exertional compartment syndrome (CECS), a definitive diagnosis is made by measuring compartment pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/4,6,7,30-35\">",
"     4,6,7,30-35",
"    </a>",
"    ]. Although, some researchers believe the history and physical examination alone may be sufficient to make the diagnosis in some instances [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/36-38\">",
"     36-38",
"    </a>",
"    ], most clinicians, including ourselves, believe compartment pressure measurements are necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/16,17,22,39\">",
"     16,17,22,39",
"    </a>",
"    ]. In most cases where we believe CECS to be the most likely diagnosis, we try conservative measures to alleviate symptoms while we complete our work-up of other possible causes, before measuring compartment pressures. (See",
"    <a class=\"local\" href=\"#H31749683\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is little high quality evidence and no agreed upon standard for diagnosing CECS on the basis of compartment pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/40\">",
"     40",
"    </a>",
"    ]. Measurement techniques, the timing of the measurements in relation to exercise, and the criteria used to diagnosis CECS vary among clinicians. Furthermore, measurements may differ among clinics depending upon the type of catheter used and whether the patient can reproduce the pain caused by exercising at the time measurements are taken. Therefore, to improve accuracy, compartment pressures should be measured by clinicians with experience performing the procedure using standardized equipment and techniques.",
"   </p>",
"   <p>",
"    Of note, some authors caution against blind, transcutaneous measurements of the deep posterior compartment of the lower leg given the potential for neurovascular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/23\">",
"     23",
"    </a>",
"    ]. Some clinicians use ultrasound to help with needle placement when measuring the deep posterior compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most widely used diagnostic criteria for CECS, which we use in our clinics, are those proposed by Pedowitz et al [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/6,16,34,42,43\">",
"     6,16,34,42,43",
"    </a>",
"    ]. According to these criteria, CECS of the leg is present if one or more of the following intramuscular pressure criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preexercise pressure &ge;15 mmHg",
"     </li>",
"     <li>",
"      1 minute postexercise pressure of &ge;30 mmHg",
"     </li>",
"     <li>",
"      5 minute postexercise pressure &ge;20 mmHg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review of studies that assessed methods for measuring compartment pressure in CECS noted that in the six studies that included a one minute postexercise compartment pressure measurement there was no overlap in the mean pressures obtained in patients (34 to 55.4 mmHg) and controls (9 to 19 mmHg) at that time, suggesting that one minute is a useful interval when obtaining pressures to diagnose CECS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/40\">",
"     40",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Direct intramuscular pressure measurement is an invasive procedure. Alternative, noninvasive means of accurately measuring muscle compartment pressures are the subject of ongoing research. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H14#H14\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Investigational techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82888729\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis of chronic exertional compartment syndrome (CECS) is made by measuring compartment pressures and finding them to be elevated in a patient whose history and physical examination suggest the diagnosis. The typical clinical presentation for CECS is a young athlete, often a runner, who describes gradually increasing pain in a specific muscle region (usually the lower leg) during physical exertion. Pain generally begins within several minutes of starting the inciting activity and resolves completely with rest, although not immediately upon stopping exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82888071\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for chronic exertional compartment syndrome (CECS) primarily includes other causes of leg pain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medial tibial stress syndrome (ie, shin splints) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link&amp;anchor=H24287212#H24287212\">",
"       \"Overview of running injuries of the lower extremity\", section on 'Medial tibial stress syndrome (shin splints) and tibial stress fractures'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stress fracture of the tibia or fibula (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19527?source=see_link\">",
"       \"Stress fractures of the tibia and fibula\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tendinopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link\">",
"       \"Overview of the management of overuse (chronic) tendinopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Deep vein thrombosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"       \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"       \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lumbar radiculopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link&amp;anchor=H14#H14\">",
"       \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\", section on 'Clinical presentations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Peripheral nerve entrapment or contusion (peroneal, saphenous, sural) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=see_link\">",
"       \"Overview of lower extremity peripheral nerve syndromes\"",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neurogenic claudication",
"     </li>",
"     <li>",
"      Vascular claudication (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\", section on 'Clinical presentation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Popliteal artery entrapment",
"     </li>",
"     <li>",
"      Cystic adventitial disease of the popliteal artery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Myopathy",
"     </li>",
"     <li>",
"      Periostitis",
"     </li>",
"     <li>",
"      Bone tumor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The history and physical examination often distinguish alternative diagnoses from CECS. As examples, medial tibial stress syndrome may be exacerbated by activities of daily living and is often only partially relieved by rest. On examination, there is often focal tenderness along the posteromedial tibial periosteum. Pain from stress fractures is often exacerbated by daily activities and causes focal tenderness over the involved portion of the tibia or fibula. Tendinopathy usually causes focal tenderness of the involved tendon and pain may be produced by testing the specific muscle group even at rest. Radiculopathies generally cause pain at rest that radiates from the lower back to the thigh and leg. In severe cases, localized weakness and diminished reflexes may be present. In nerve entrapment syndromes, paresthesias, numbness, and burning sensations that radiate are more prominent and examination may reveal weakness or atrophy of the muscles innervated by the involved nerve. Pain induced by tapping the site of entrapment (positive Tinel sign) may be noted [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31749683\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many conditions can mimic chronic exertional compartment syndrome CECS and definitive diagnosis requires invasive measurement of compartment pressures. Therefore, we investigate other potential causes of exertional leg pain and attempt conservative management prior to measuring pressures. Conservative interventions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Running on softer surfaces",
"     </li>",
"     <li>",
"      Using orthotics, other shoe inserts, or better athletic shoes",
"     </li>",
"     <li>",
"      Reducing training volume: patients may cross train (combine cycling or swimming with reduced running) to maintain fitness, then gradually increase their running once symptoms resolve",
"     </li>",
"     <li>",
"      Addressing deficiencies in strength or flexibility with physical therapy",
"     </li>",
"     <li>",
"      Icing the affected area after training &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the work-up for other potential causes of exertional pain is unrevealing, and conservative management fails to alleviate symptoms, we proceed with compartment pressure measurements. &nbsp;",
"   </p>",
"   <p>",
"    Cessation of inciting activities resolves symptoms in most cases of CECS. However, this solution is unacceptable to many athletes. Such patients should be referred to an orthopedic surgeon for possible muscle compartment release. To date, no alternative nonoperative approach has been successful for treating refractory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/2,16,23,24,42\">",
"     2,16,23,24,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical management using either fasciotomy or fasciectomy yields good results in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/24,33,34,36,38,47-49\">",
"     24,33,34,36,38,47-49",
"    </a>",
"    ], although reported success rates vary [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/43,50\">",
"     43,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H428235599#H428235599\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Alternative fasciotomy techniques for elective compartment decompression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical cure rates are higher in CECS involving the anterior and lateral compartments than the deep posterior compartment of the lower leg [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/33,34,47,49,50\">",
"     33,34,47,49,50",
"    </a>",
"    ]. Surgical treatment may be less effective in female athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31749690\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some authors prefer partial open fasciectomy to simple fasciotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/4,23\">",
"     4,23",
"    </a>",
"    ]. In an observational study of CECS, 109 patients underwent open fasciectomy with extended subcutaneous fasciotomy while 100 patients underwent subcutaneous fasciotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/23\">",
"     23",
"    </a>",
"    ]. Symptoms recurred less often in the open fasciectomy group (2 percent) than the fasciotomy group (11 percent). In addition, lower rates of intraoperative and early postoperative complications were reported in the open fasciectomy group. Other authors have not found a significant long-term benefit from partial fasciectomy and fasciotomy over simple fasciotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31749690\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Without cessation of symptom-inducing activities, the prognosis for chronic exertional compartment syndrome (CECS) is poor if treated nonoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/2,16,23,24,42\">",
"     2,16,23,24,42",
"    </a>",
"    ]. Although success rates vary by compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/43,50\">",
"     43,50",
"    </a>",
"    ], surgical treatment appears to give better outcomes, with several observational studies showing significant pain relief and functional improvement in more than 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/3,4,10,23\">",
"     3,4,10,23",
"    </a>",
"    ]. However, no prospective randomized trials have been conducted. Recurrent symptoms occur in approximately 3.4 to 11 percent of patients, and these are often treated with additional surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/3,4,10,23\">",
"     3,4,10,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical success rates may be lower in female athletes for reasons that remain unclear. One review of women treated surgically for CECS reported a success rate of 76 percent and the authors noted that other published studies confirm higher failure rates among women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/42\">",
"     42",
"    </a>",
"    ]. Decisions about when athletes can return to sports are generally made by the surgeon, but case series report that athletes return between 8 to 12 weeks postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28215/abstract/34,47\">",
"     34,47",
"    </a>",
"    ] &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25985?source=see_link\">",
"       \"Patient information: Chronic compartment syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31749697\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic exertional compartment syndrome (CECS) is an overuse injury that typically affects young endurance athletes, particularly distance runners. (See",
"      <a class=\"local\" href=\"#H31749655\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31749662\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain develops in the involved compartment, usually in the lower leg, shortly after the start of exercise and resolves once exercise is stopped. Pain is often bilateral. (See",
"      <a class=\"local\" href=\"#H31749669\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many conditions can mimic CECS. (See",
"      <a class=\"local\" href=\"#H82888071\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical examination is often unremarkable with CECS and the condition is often misdiagnosed initially. Diagnosis is ultimately confirmed by direct measurement of compartment pressures. (See",
"      <a class=\"local\" href=\"#H502554\">",
"       'Compartment pressure measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management consists of conservative measures, such as reducing training volume, addressing strength or flexibility deficiencies, and using orthotics. (See",
"      <a class=\"local\" href=\"#H31749683\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms resolve with cessation of the inciting activity. Patients unwilling to stop such activity are referred for surgical evaluation.",
"     </li>",
"     <li>",
"      Surgical treatment consists of either fasciotomy or fasciectomy and is usually successful. Success rates vary depending upon the involved compartment. Female patients appear to have lower surgical cure rates.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/1\">",
"      MAVOR GE. The anterior tibial syndrome. J Bone Joint Surg Br 1956; 38-B:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/2\">",
"      Barnes M. Diagnosis and management of chronic compartment syndromes: a review of the literature. Br J Sports Med 1997; 31:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/3\">",
"      Detmer DE. Diagnosis and management of chronic compartment syndrome of the leg. Semin Orthop 1988; 3:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/4\">",
"      Turnipseed WD. Diagnosis and management of chronic compartment syndrome. Surgery 2002; 132:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/5\">",
"      Qvarfordt P, Christenson JT, Ekl&ouml;f B, et al. Intramuscular pressure, muscle blood flow, and skeletal muscle metabolism in chronic anterior tibial compartment syndrome. Clin Orthop Relat Res 1983; :284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/6\">",
"      Pedowitz RA, Hargens AR, Mubarak SJ, Gershuni DH. Modified criteria for the objective diagnosis of chronic compartment syndrome of the leg. Am J Sports Med 1990; 18:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/7\">",
"      Styf JR, K&ouml;rner LM. Diagnosis of chronic anterior compartment syndrome in the lower leg. Acta Orthop Scand 1987; 58:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/8\">",
"      Touliopolous S, Hershman EB. Lower leg pain. Diagnosis and treatment of compartment syndromes and other pain syndromes of the leg. Sports Med 1999; 27:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/9\">",
"      Reneman RS. The anterior and the lateral compartmental syndrome of the leg due to intensive use of muscles. Clin Orthop Relat Res 1975; :69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/10\">",
"      Detmer DE, Sharpe K, Sufit RL, Girdley FM. Chronic compartment syndrome: diagnosis, management, and outcomes. Am J Sports Med 1985; 13:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/11\">",
"      Padhiar N, Allen M, King JB. Chronic exertional compartment syndrome of the foot. Sports Med Arthrosc 2009; 17:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/12\">",
"      Fontes D, Clement R, Roure P. [Endoscopic aponeurotomy for chronic exertional compartmental syndrome of the forearm: report of 41 cases]. Chir Main 2003; 22:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/13\">",
"      Botte MJ, Fronek J, Pedowitz RA, et al. Exertional compartment syndrome of the upper extremity. Hand Clin 1998; 14:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/14\">",
"      Birnbaum J. Recurrent compartment syndrome in the posterior thigh. Am J Sports Med 1983; 11:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/15\">",
"      Black KP, Schultz TK, Cheung NL. Compartment syndromes in athletes. Clin Sports Med 1990; 9:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/16\">",
"      Shah SN, Miller BS, Kuhn JE. Chronic exertional compartment syndrome. Am J Orthop (Belle Mead NJ) 2004; 33:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/17\">",
"      Wilder RP, Magrum E. Exertional compartment syndrome. Clin Sports Med 2010; 29:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/18\">",
"      Matsen FA 3rd, Wyss CR, Krugmire RB Jr, et al. The effects of limb elevation and dependency on local arteriovenous gradients in normal human limbs with particular reference to limbs with increased tissue pressure. Clin Orthop Relat Res 1980; :187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/19\">",
"      Mohler LR, Styf JR, Pedowitz RA, et al. Intramuscular deoxygenation during exercise in patients who have chronic anterior compartment syndrome of the leg. J Bone Joint Surg Am 1997; 79:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/20\">",
"      Styf J, K&ouml;rner L, Suurkula M. Intramuscular pressure and muscle blood flow during exercise in chronic compartment syndrome. J Bone Joint Surg Br 1987; 69:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/21\">",
"      Turnipseed WD, Hurschler C, Vanderby R Jr. The effects of elevated compartment pressure on tibial arteriovenous flow and relationship of mechanical and biochemical characteristics of fascia to genesis of chronic anterior compartment syndrome. J Vasc Surg 1995; 21:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/22\">",
"      Bong MR, Polatsch DB, Jazrawi LM, Rokito AS. Chronic exertional compartment syndrome: diagnosis and management. Bull Hosp Jt Dis 2005; 62:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/23\">",
"      Turnipseed W, Detmer DE, Girdley F. Chronic compartment syndrome. An unusual cause for claudication. Ann Surg 1989; 210:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/24\">",
"      Fronek J, Mubarak SJ, Hargens AR, et al. Management of chronic exertional anterior compartment syndrome of the lower extremity. Clin Orthop Relat Res 1987; :217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/25\">",
"      Balduini FC, Shenton DW, O'Connor KH, Heppenstall RB. Chronic exertional compartment syndrome: correlation of compartment pressure and muscle ischemia utilizing 31P-NMR spectroscopy. Clin Sports Med 1993; 12:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/26\">",
"      Owens S, Edwards P, Miles K, et al. Chronic compartment syndrome affecting the lower limb: MIBI perfusion imaging as an alternative to pressure monitoring: two case reports. Br J Sports Med 1999; 33:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/27\">",
"      Amendola A, Rorabeck CH, Vellett D, et al. The use of magnetic resonance imaging in exertional compartment syndromes. Am J Sports Med 1990; 18:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/28\">",
"      Trease L, van Every B, Bennell K, et al. A prospective blinded evaluation of exercise thallium-201 SPET in patients with suspected chronic exertional compartment syndrome of the leg. Eur J Nucl Med 2001; 28:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/29\">",
"      Takebayashi S, Takazawa H, Sasaki R, et al. Chronic exertional compartment syndrome in lower legs: localization and follow-up with thallium-201 SPECT imaging. J Nucl Med 1997; 38:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/30\">",
"      Hargens AR, Mubarak SJ, Owen CA, et al. Interstitial fluid pressure in muscle and compartment syndromes in man. Microvasc Res 1977; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/31\">",
"      Martens MA, Backaert M, Vermaut G, Mulier JC. Chronic leg pain in athletes due to a recurrent compartment syndrome. Am J Sports Med 1984; 12:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/32\">",
"      Qvarfordt P, Ekl&ouml;f B, Ohlin P. Reference values for intramuscular pressure in the lower leg in man. Clin Physiol 1982; 2:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/33\">",
"      Rorabeck CH, Bourne RB, Fowler PJ. The surgical treatment of exertional compartment syndrome in athletes. J Bone Joint Surg Am 1983; 65:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/34\">",
"      Schepsis AA, Martini D, Corbett M. Surgical management of exertional compartment syndrome of the lower leg. Long-term followup. Am J Sports Med 1993; 21:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/35\">",
"      Styf J. Diagnosis of exercise-induced pain in the anterior aspect of the lower leg. Am J Sports Med 1988; 16:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/36\">",
"      Almdahl SM, Samdal F. Fasciotomy for chronic compartment syndrome. Acta Orthop Scand 1989; 60:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/37\">",
"      Mannarino F, Sexson S. The significance of intracompartmental pressures in the diagnosis of chronic exertional compartment syndrome. Orthopedics 1989; 12:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/38\">",
"      Sudmann E. The painful chronic anterior lower leg syndrome. A prospective clinical and experimental study. Acta Orthop Scand 1979; 50:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/39\">",
"      Tzortziou V, Maffulli N, Padhiar N. Diagnosis and management of chronic exertional compartment syndrome (CECS) in the United Kingdom. Clin J Sport Med 2006; 16:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/40\">",
"      Aweid O, Del Buono A, Malliaras P, et al. Systematic review and recommendations for intracompartmental pressure monitoring in diagnosing chronic exertional compartment syndrome of the leg. Clin J Sport Med 2012; 22:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/41\">",
"      Wiley JP, Short WB, Wiseman DA, Miller SD. Ultrasound catheter placement for deep posterior compartment pressure measurements in chronic compartment syndrome. Am J Sports Med 1990; 18:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/42\">",
"      Micheli LJ, Solomon R, Solomon J, et al. Surgical treatment for chronic lower-leg compartment syndrome in young female athletes. Am J Sports Med 1999; 27:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/43\">",
"      Slimmon D, Bennell K, Brukner P, et al. Long-term outcome of fasciotomy with partial fasciectomy for chronic exertional compartment syndrome of the lower leg. Am J Sports Med 2002; 30:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/44\">",
"      Yang LJ, Gala VC, McGillicuddy JE. Superficial peroneal nerve syndrome: an unusual nerve entrapment. Case report. J Neurosurg 2006; 104:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/45\">",
"      Fabre T, Montero C, Gaujard E, et al. Chronic calf pain in athletes due to sural nerve entrapment. A report of 18 cases. Am J Sports Med 2000; 28:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/46\">",
"      Ni Mhuircheartaigh N, Kavanagh E, O'Donohoe M, Eustace S. Pseudo compartment syndrome of the calf in an athlete secondary to cystic adventitial disease of the popliteal artery. Br J Sports Med 2005; 39:e36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/47\">",
"      Rorabeck CH, Fowler PJ, Nott L. The results of fasciotomy in the management of chronic exertional compartment syndrome. Am J Sports Med 1988; 16:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/48\">",
"      Styf JR, K&ouml;rner LM. Chronic anterior-compartment syndrome of the leg. Results of treatment by fasciotomy. J Bone Joint Surg Am 1986; 68:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/49\">",
"      Wallensten R, Eklund B. Intramuscular pressures and muscle metabolism after short-term and long-term exercise. Int J Sports Med 1983; 4:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28215/abstract/50\">",
"      van Zoest WJ, Hoogeveen AR, Scheltinga MR, et al. Chronic deep posterior compartment syndrome of the leg in athletes: postoperative results of fasciotomy. Int J Sports Med 2008; 29:419.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13859 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28215=[""].join("\n");
var outline_f27_35_28215=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31749697\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31749648\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31749655\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31749662\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31749669\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H504249\">",
"      DIAGNOSTIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H502554\">",
"      COMPARTMENT PRESSURE MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H82888729\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H82888071\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31749683\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31749690\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31749697\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13859\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13859|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/33/26137\" title=\"figure 1\">",
"      Cross section of the leg and forearm compartments",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=related_link\">",
"      Lower extremity fasciotomy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=related_link\">",
"      Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=related_link\">",
"      Overview of running injuries of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=related_link\">",
"      Overview of the management of overuse (chronic) tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25985?source=related_link\">",
"      Patient information: Chronic compartment syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19527?source=related_link\">",
"      Stress fractures of the tibia and fibula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_35_28216="Insect bites";
var content_f27_35_28216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Insect bites",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/35/28216/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28216/contributors\">",
"     Mariana C Castells, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/35/28216/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28216/contributors\">",
"     David B Golden, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28216/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28216/contributors\">",
"     Ted Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/35/28216/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28216/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28216/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/35/28216/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bites of insects may be a minor nuisance or may lead to serious medical problems, including transmission of insect-borne illnesses and severe allergic reactions. Arthropods that commonly bite humans include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mosquitoes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23011?source=see_link\">",
"       \"Mosquito vectors of infectious diseases\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ticks",
"     </li>",
"     <li>",
"      Fleas",
"     </li>",
"     <li>",
"      Kissing bugs (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36615?source=see_link\">",
"       \"Reactions to bites from kissing bugs (Triatoma)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bedbugs (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39286?source=see_link\">",
"       \"Bedbugs\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Blackflies",
"     </li>",
"     <li>",
"      Sandflies",
"     </li>",
"     <li>",
"      Chiggers (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43556?source=see_link\">",
"       \"Chigger bites\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Biting midges (no-see-ums)",
"     </li>",
"     <li>",
"      A small number of types of spiders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=see_link\">",
"       \"Approach to the patient with a suspected spider bite: An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24248?source=see_link\">",
"       \"Bites of recluse spiders\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25081?source=see_link\">",
"       \"Bites of widow spiders\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reactions to the bites of mosquitoes, ticks, fleas, blackflies, and sandflies are discussed in this topic review. Infectious diseases transmitted by the bites of mosquitoes, ticks, fleas, kissing bugs and sandflies are discussed in detail separately.",
"   </p>",
"   <p>",
"    Insect bites are different from insect stings. Stings involve the injection of venom into the victim and may cause reactions ranging from local irritation to life threatening anaphylaxis. The medical consequences of various insect stings are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=see_link\">",
"     \"Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7994?source=see_link\">",
"     \"Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insect bites may result in local reactions, papular urticaria, or systemic allergic reactions. Rarely, other forms of systemic reactions occur, such as serum sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Local reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal reaction to an insect bite is an inflammatory reaction at the site of the punctured skin, which appears within minutes and consists of pruritic local erythema and edema. Symptoms usually subside within a few hours. Local reactions are caused by irritant substances concentrated in insect saliva (anticoagulants, enzymes, agglutinins and mucopolysaccharides). In some cases, a local reaction is followed by a delayed skin reaction consisting of local swelling, itching, and redness. Evolution to a vesicular, bullous, indurated, or necrotic lesion is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunocompromised patients, such as those with AIDS, chronic lymphocytic leukemia, histiocytosis-X disorders, and disorders of monocyte function, may develop severe local bite reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/2-6\">",
"       2-6",
"      </a>",
"      ]. In such patients, local reactions can progress to become necrotic, or may be accompanied by systemic symptoms, including lymphadenopathy and fever. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Insect stings and bites'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with delusional parasitosis believe they are being bitten by imaginary insects. Similarly, amphetamine and cocaine abusers with formication (a feeling that ants are crawling on the skin) can present with self-inflicted skin lesions from an imaginary infestation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/4/3145?source=see_link\">",
"       \"Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=see_link\">",
"       \"Methamphetamine intoxication\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514913\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insect bites should be washed with soap and water. Reduction of local edema may be induced with cooling (ice or cold pack). Topical creams, gels and lotions such as those containing calamine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/5/17491?source=see_link\">",
"     pramoxine",
"    </a>",
"    decrease pruritus. Routine use of topical anesthetic and antihistamine preparations should be avoided because they can sensitize the skin following sun exposure and induce allergic contact sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonsedating oral antihistamines such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    (10 mg once a day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    (10 mg once a day) may be helpful for patients with troublesome itching. The sedating agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    (HCL or pamoate) (10 to 25 mg every four to six hours as needed) may be helpful for controlling pruritus in adults. H1 and H2 antihistamines may be used concurrently.",
"   </p>",
"   <p>",
"    Concurrent use of oral H1 antihistamines and topical antihistamines applied over large surface areas should be avoided, because this combination can cause systemic anticholinergic toxicity.",
"   </p>",
"   <p>",
"    Dramatic local swelling can be reduced with a brief course of oral glucocorticoids, although this should be reserved for severe cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Papular urticaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papular urticaria is a hypersensitivity disorder in which insect bites, most often those of fleas, mosquitoes, or bedbugs, lead to recurrent and sometimes chronic itchy papules on exposed areas of skin (eg, arms, lower legs, upper back, scalp) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Papular urticaria is reported predominantly in young children (typically 2 to 10 years of age). The",
"    <span class=\"nowrap\">",
"     diaper/underwear",
"    </span>",
"    areas, genital, perianal, and axillary areas are spared [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/10\">",
"     10",
"    </a>",
"    ]. The 0.5 to 1 cm lesions may be urticarial at the start of the syndrome, but become persistent and papular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nodular with time (",
"    <a class=\"graphic graphic_picture graphicRef78529 \" href=\"UTD.htm?35/4/35919\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50494 \" href=\"UTD.htm?28/6/28783\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnosis of papular urticaria is made clinically, although there may be a delay between the inciting bite(s) and the onset of lesions, or insect bites may not have been noticed at all [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/10\">",
"     10",
"    </a>",
"    ]. Usually only one child in a family is affected, a clue that infestation at home is unlikely. New lesions may appear sporadically, and renewed itching may lead to reactivation of older lesions, leading to a chronic and cycling disorder that may last from months to years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514948\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of papular urticaria includes selective and limited use of nonsedating antihistamines for pruritus, topical steroids applied to individual lesions, and reassurance, as the disorder eventually resolves spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Systemic allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic allergic reactions to insect bites are uncommon, but do occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/11\">",
"     11",
"    </a>",
"    ]. Systemic allergic reactions have been described in response to the bite of Triatoma (kissing bugs), mosquitoes, ticks, blackflies, deerflies, louseflies, and horseflies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. Reactions to Triatoma are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36615?source=see_link\">",
"     \"Reactions to bites from kissing bugs (Triatoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with mast cell disorders may develop severe systemic allergic reactions following insect bites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/17\">",
"     17",
"    </a>",
"    ]. Reactions can result following insect bites, stings of Hymenoptera insects, and a variety of other triggers, which cause widespread activation of mast cells with prominent flushing and hypotension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .) Patients with serum tryptase levels above 5 to 8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    are at risk for severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic reactions to Hymenoptera and insects, even in the absence of systemic mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514983\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis associated with insect bites needs to be treated promptly with epinephrine. Patients who have experienced systemic reactions should be supplied with an epinephrine autoinjector and instructed in how and when to use it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H39#H39\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Discharge care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=see_link\">",
"     \"Prescribing epinephrine for anaphylaxis self-treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Referral to an allergy specialist should be facilitated whenever possible. Allergy specialists are able to assess the patient&rsquo;s clinical history to assure that the correct trigger for the allergic reaction has been identified and in some cases, perform confirmatory testing. For patients who have suffered anaphylaxis, allergists are able to provide effective training in the self-injection of epinephrine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SPECIFIC ARTHROPOD BITES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mosquitoes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly occurring insect bites are inflicted by mosquitoes, of the family Culicidae (order Diptera). The genera Anopheles, Culex, and Aedes are usually responsible for human bites. Mosquitoes are often found around standing water since they need an aquatic environment to complete their life cycle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23011?source=see_link\">",
"     \"Mosquito vectors of infectious diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Local reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local pain, pruritus, and erythema are typical after a mosquito bite. Common reactions include an immediate wheal and flare response that peaks at about 20 minutes, or an indurated pruritic papule that peaks at two to three days and resolves over the ensuing days to weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some people, particularly young children, can develop very dramatic swelling surrounding the site of the bite that may be accompanied by low grade fever and mistaken for cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/21\">",
"     21",
"    </a>",
"    ]. Other uncommon local reactions include ecchymosis, vesiculation, or blistering at the site. In many patients, these exaggerated local reactions improve with age and can be managed with prophylactic antihistamines during the summer months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41766?source=see_link\">",
"     \"Large local reactions to mosquito bites (Skeeter Syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with Epstein-Barr virus-associated lymphoproliferative disorders may develop necrotic skin lesions at the site of mosquito bites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/6,24-27\">",
"     6,24-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Insect stings and bites'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic reactions due to mosquito bites have been reported:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1284671\">",
"    <span class=\"h4\">",
"     Allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can experience classical anaphylaxis, presenting with some combination of generalized urticaria, angioedema, wheezing, vomiting, hypotension, loss of consciousness, or other manifestations of anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/20,21,28\">",
"     20,21,28",
"    </a>",
"    ]. The commercially-available whole body extracts for mosquito had limited diagnostic utility and were shown to be positive in only 25 percent of individuals with convincing histories of anaphylaxis in one series of 14 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/29\">",
"     29",
"    </a>",
"    ]. More specific recombinant salivary antigens have been produced in research settings and new diagnostic tests should be available in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/21,29,30\">",
"     21,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1284678\">",
"    <span class=\"h4\">",
"     Other systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systemic reaction of uncertain pathogenesis was described in a Japanese report of two patients with local skin reactions, fever, fatigue, nausea, anorexia, and hepatosplenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514639\">",
"    <span class=\"h3\">",
"     Disease transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diseases transmitted by mosquitoes in the United States include West Nile virus, St. Louis encephalitis, and LaCrosse encephalitis. Mosquitoes do not transmit HIV infection since the virus neither survives nor replicates well in mosquitoes, and blood from one meal is not flushed into the next host [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/32\">",
"     32",
"    </a>",
"    ]. Diseases transmitted by mosquitoes worldwide include malaria, yellow fever, dengue hemorrhagic fever, chikungunya and other arboviruses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=see_link\">",
"     \"Diagnosis of malaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15705?source=see_link\">",
"     \"Yellow fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15576?source=see_link\">",
"     \"Chikungunya fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=see_link\">",
"     \"Arthropod-borne encephalitides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=see_link\">",
"     \"Clinical presentation and diagnosis of dengue virus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ticks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tick bites are primarily of concern because they can transmit infectious diseases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lyme borreliosis is one of the most frequently reported tick-borne human diseases. It is caused by the spirochete Borrelia burgdorferi, which is transmitted by the bite of infected Ixodes ticks: I. scapularis (",
"      <a class=\"graphic graphic_picture graphicRef73802 \" href=\"UTD.htm?14/13/14558\">",
"       picture 3",
"      </a>",
"      ) in the Eastern and North central United States; I. pacificus (",
"      <a class=\"graphic graphic_picture graphicRef60501 \" href=\"UTD.htm?26/25/27038\">",
"       picture 4",
"      </a>",
"      ) in the Western United States; I. ricinus in Europe; and I. persulcatus in Asia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=see_link\">",
"       \"Evaluation of a tick bite for possible Lyme disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"       \"Epidemiology of Lyme disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The principal vector of Rocky Mountain spotted fever in the eastern and south central United States is Dermacentor variabilis (the American dog tick) (",
"      <a class=\"graphic graphic_picture graphicRef71719 \" href=\"UTD.htm?19/57/20383\">",
"       picture 5",
"      </a>",
"      ). Dermacentor andersonii (the Rocky Mountain wood tick) (",
"      <a class=\"graphic graphic_picture graphicRef68829 \" href=\"UTD.htm?21/18/21806\">",
"       picture 6",
"      </a>",
"      ) is the primary vector in the mountain states west of the Mississippi River. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31364?source=see_link\">",
"       \"Biology of Rickettsia rickettsii infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Human ehrlichiosis, babesiosis and tularemia may be transmitted by the Lone Star tick (Amblyomma americanum) (",
"      <a class=\"graphic graphic_picture graphicRef71086 \" href=\"UTD.htm?23/1/23582\">",
"       picture 7",
"      </a>",
"      ) and Ixodes scapularis (",
"      <a class=\"graphic graphic_picture graphicRef73802 \" href=\"UTD.htm?14/13/14558\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=see_link\">",
"       \"Human ehrlichiosis and anaplasmosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39321?source=see_link\">",
"       \"Clinical manifestations, diagnosis, treatment, and prevention of babesiosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bites of some ticks can cause rare systemic allergic reactions, which have been reported with bites from the Ixodes tick, Ixodes holocyclus (the Australian paralysis tick), and Argas reflexus (the European pigeon tick) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Salivary proteins of ticks are thought to be allergenic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, in the Southeastern United States, tick bites have been implicated in sensitizing patients to a carbohydrate determinant also found in the drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and some meats, resulting in allergic reactions to these substances, instead of to tick bites directly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H48#H48\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Cetuximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36072?source=see_link&amp;anchor=H8#H8\">",
"     \"Allergy to meats\", section on 'Meats and monoclonal antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Flies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various fly species are capable of inducing allergic reactions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transmitting infectious diseases. Blackflies, horseflies, deerflies, louseflies, and sandflies have been reported to induce systemic allergic and inflammatory reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blackflies have been implicated in anaphylaxis and in a late systemic syndrome characterized by fever, leukocytosis, lymphadenitis, and papular lesions.",
"     </li>",
"     <li>",
"      Horseflies and deerflies inflict painful bites; there have been several reports of systemic anaphylaxis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514823\">",
"    <span class=\"h3\">",
"     Disease transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flies can serve as vectors of infectious diseases in geographic regions that support transmission of specific pathogens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The simulium black fly is the vector for onchocerciasis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20970?source=see_link\">",
"       \"Onchocerciasis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Sandflies are capable of transmitting bartonellosis and leishmaniasis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26503?source=see_link\">",
"       \"Bartonellosis: Oroya fever and verruga peruana\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cutaneous leishmaniasis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/20/42308?source=see_link\">",
"       \"Epidemiology and control of visceral leishmaniasis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Houseflies have been implicated in transmission of enteric infections in settings where facilities for clean water and hygienic practices are limited (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=see_link\">",
"       \"Pathogenic Escherichia coli\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Shigella infection\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Myiasis, or skin nodules caused by fly larvae embedded in the skin, are usually seen in patients or travelers from tropical areas. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20152?source=see_link&amp;anchor=H8401226#H8401226\">",
"       \"Skin lesions in the returning traveler\", section on 'Myiasis'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fleas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fleas (order Siphonaptera) inflict bites that are usually papules arranged in a non-follicular pattern (",
"    <a class=\"graphic graphic_picture graphicRef54271 \" href=\"UTD.htm?9/11/9396\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef78799 \" href=\"UTD.htm?13/63/14321\">",
"     picture 9",
"    </a>",
"    ). Flea bites can induce papular urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Papular urticaria'",
"    </a>",
"    above.) Flea allergy may cause respiratory symptoms in humans, particularly in patients allergic to cats, although anaphylaxis has not been reported.",
"   </p>",
"   <p>",
"    Eradication of fleas in homes without an obvious animal vector involves insecticidal dusts or sprays, vacuuming, and cleaning [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/41\">",
"     41",
"    </a>",
"    ]. Consultation with a veterinarian is advised if",
"    <span class=\"nowrap\">",
"     pets/animals",
"    </span>",
"    are believed to be the source of the infestation, since direct treatment of the pet is usually required [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Fleas play a role in the transmission of several infectious diseases as a component of epidemiologic cycles that also include animals and humans. Examples include plague (Yersinia pestis), bartonellosis, typhus and tungiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36583?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Bartonella quintana infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27796?source=see_link\">",
"     \"The epidemiology and clinical manifestations of murine typhus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20152?source=see_link\">",
"     \"Skin lesions in the returning traveler\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20152?source=see_link&amp;anchor=H8401410#H8401410\">",
"     \"Skin lesions in the returning traveler\", section on 'Tungiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17788716\">",
"    <span class=\"h2\">",
"     Biting midges (no-see-ums)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biting midges (genus Culicoides) are found worldwide. They are tiny",
"    <span class=\"nowrap\">",
"     gray/black,",
"    </span>",
"    winged insects that are less than 3 mm in length. The term &ldquo;no-see-um&rdquo; comes from the fact that people often feel the sharp, burning bite, but are unable to see the midge. Females require blood in order to produce mature eggs and typically feed at dawn and dusk. Coastal areas and marshlands are preferred breeding habitats [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Bites may result in small welts or localized allergic reactions in sensitive individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In a Taiwanese series of 220 subjects, local reactions ranged from immediate (ie, within one hour) to immediate followed by delayed, to isolated delayed reactions consisting of pruritic papules or vesicles that could persist for weeks to months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28216/abstract/46\">",
"     46",
"    </a>",
"    ]. A small number of patients had systemic symptoms of fever and lymphadenopathy.",
"   </p>",
"   <p>",
"    Biting midges can transmit filarial worms of the Mansonella species in South and Central America, as well as parts of Africa and the Caribbean. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=see_link\">",
"     \"Loiasis (Loa loa infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H762114\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several dermatologic disorders can present with scattered inflammatory papules that may resemble arthropod bites. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Folliculitis &ndash;",
"      </strong>",
"      Superficial folliculitis is characterized by small, follicularly-based inflammatory papules and pustules (",
"      <a class=\"graphic graphic_picture graphicRef50187 graphicRef62930 \" href=\"UTD.htm?12/26/12714\">",
"       picture 10A-B",
"      </a>",
"      ). Cultures taken from pustular lesions are useful for identifying causative organisms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22387?source=see_link\">",
"       \"Folliculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lymphomatoid papulosis &ndash;",
"      </strong>",
"      Lymphomatoid papulosis is an uncommon chronic, recurrent skin disorder that presents with red-brown papules or nodules that typically persist for several weeks (",
"      <a class=\"graphic graphic_picture graphicRef77791 \" href=\"UTD.htm?41/60/42946\">",
"       picture 11",
"      </a>",
"      ). Lesions are often asymptomatic, and may be crusted, necrotic, or hemorrhagic. Progression to mycosis fungoides, anaplastic large cell lymphoma, or Hodgkin disease occurs in a minority of patients. The diagnosis is confirmed via skin biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=see_link\">",
"       \"Lymphomatoid papulosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pityriasis lichenoides et varioliformis acuta (PLEVA) &ndash;",
"      </strong>",
"      PLEVA is a rare benign skin disease that presents with recurrent crops of inflammatory papules (",
"      <a class=\"graphic graphic_picture graphicRef57911 \" href=\"UTD.htm?9/29/9685\">",
"       picture 12",
"      </a>",
"      ). Lesions may demonstrate ulceration, vesiculation, pustulation, or crusting. Skin biopsies assist with diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17369?source=see_link\">",
"       \"Pityriasis lichenoides et varioliformis acuta (PLEVA)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=see_link\">",
"       \"Patient information: Insect bites and stings (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/22/18786?source=see_link\">",
"       \"Patient information: Bee and insect stings (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most insect bites cause local inflammatory reactions that subside within a few hours without complications. However, more severe local symptoms, papular urticaria, systemic allergic reactions, and transmission of a disease-causing pathogen are also possible. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mosquito bites can cause varying degrees of local swelling, papular urticaria in children, and rare systemic allergic reactions, including anaphylaxis. Several pathogens are transmitted by mosquitoes in the United States, including the vectors for West Nile virus, St. Louis encephalitis, and LaCrosse encephalitis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mosquitoes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ticks bites are mainly of concern because ticks can transmit infectious pathogens (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Ticks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various fly species are capable of inducing systemic allergic reactions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      transmitting infectious diseases. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Flies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flea bites are usually only a nuisance, but children can develop papular urticaria and bites can transmit infectious diseases. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Fleas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/1\">",
"      Gaig P, Garc&iacute;a-Ortega P, Enrique E, et al. Serum sickness-like syndrome due to mosquito bite. J Investig Allergol Clin Immunol 1999; 9:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/2\">",
"      Engler RJ. Mosquito bite pathogenesis in necrotic skin reactors. Curr Opin Allergy Clin Immunol 2001; 1:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/3\">",
"      Penneys NS, Nayar JK, Bernstein H, Knight JW. Chronic pruritic eruption in patients with acquired immunodeficiency syndrome associated with increased antibody titers to mosquito salivary gland antigens. J Am Acad Dermatol 1989; 21:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/4\">",
"      Vassallo C, Passamonti F, Cananzi R, et al. Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases. Acta Derm Venereol 2005; 85:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/5\">",
"      Wakimoto N, Niitsu N. Lymphoid neoplasms associated with mosquito bites. Intern Med 2005; 44:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/6\">",
"      Asada H. Hypersensitivity to mosquito bites: a unique pathogenic mechanism linking Epstein-Barr virus infection, allergy and oncogenesis. J Dermatol Sci 2007; 45:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/7\">",
"      Reunala T, Lappalainen P, Brummer-Korvenkontio H, et al. Cutaneous reactivity to mosquito bites: effect of cetirizine and development of anti-mosquito antibodies. Clin Exp Allergy 1991; 21:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/8\">",
"      Demain JG. Papular urticaria and things that bite in the night. Curr Allergy Asthma Rep 2003; 3:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/9\">",
"      Steen CJ, Carbonaro PA, Schwartz RA. Arthropods in dermatology. J Am Acad Dermatol 2004; 50:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/10\">",
"      Hernandez RG, Cohen BA. Insect bite-induced hypersensitivity and the SCRATCH principles: a new approach to papular urticaria. Pediatrics 2006; 118:e189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/11\">",
"      Frazier CA. Biting insects. Arch Dermatol 1973; 107:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/12\">",
"      Vidal C, Armis&eacute;n M, Bartolom&eacute; B, et al. Anaphylaxis to Hippobosca equina (louse fly). Ann Allergy Asthma Immunol 2007; 99:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/13\">",
"      Hrabak TM, Dice JP. Use of immunotherapy in the management of presumed anaphylaxis to the deer fly. Ann Allergy Asthma Immunol 2003; 90:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/14\">",
"      Hassoun S, Drouet M, Sabbah A. [Anaphylaxis caused by a mosquito: 2 case reports]. Allerg Immunol (Paris) 1999; 31:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/15\">",
"      Stevens WJ, Van den Abbeele J, Bridts CH. Anaphylactic reaction after bites by Glossina morsitans (tsetse fly) in a laboratory worker. J Allergy Clin Immunol 1996; 98:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/16\">",
"      Decastello A, Farkas R. [Anaphylactic reaction caused by a horse-fly species (Hippobosca equina)]. Orv Hetil 2009; 150:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/17\">",
"      Potier A, Lavigne C, Chappard D, et al. Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase. Clin Exp Allergy 2009; 39:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/18\">",
"      Ru&euml;ff F, Przybilla B, Bil&oacute; MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/19\">",
"      Bonadonna P, Zanotti R, Pagani M, et al. How much specific is the association between hymenoptera venom allergy and mastocytosis? Allergy 2009; 64:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/20\">",
"      Peng Z, Simons FE. Mosquito allergy: immune mechanisms and recombinant salivary allergens. Int Arch Allergy Immunol 2004; 133:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/21\">",
"      Peng Z, Simons FE. Advances in mosquito allergy. Curr Opin Allergy Clin Immunol 2007; 7:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/22\">",
"      Lelong M, Bras C, Castelain C, Drain JP. [Severe local reactions to mosquito bites. Apropos of 20 cases]. Allerg Immunol (Paris) 1986; 18:19, 21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/23\">",
"      Peng Z, Ho MK, Li C, Simons FE. Evidence for natural desensitization to mosquito salivary allergens: mosquito saliva specific IgE and IgG levels in children. Ann Allergy Asthma Immunol 2004; 93:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/24\">",
"      Kanno H, Onodera H, Endo M, et al. Vascular lesion in a patient of chronic active Epstein-Barr virus infection with hypersensitivity to mosquito bites: vasculitis induced by mosquito bite with the infiltration of nonneoplastic Epstein-Barr virus-positive cells and subsequent development of natural killer/T-cell lymphoma with angiodestruction. Hum Pathol 2005; 36:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/25\">",
"      Yoon TY, Kim YG, Kim JW, Kim MK. Nodal marginal zone lymphoma in association with hydroa vacciniforme-like papulovesicular eruption, hypersensitivity to mosquito bites and insect bite-like reaction. Br J Dermatol 2005; 153:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/26\">",
"      Yamamoto T, Fujii K, Tsuji K, et al. Characterization of Epstein-Barr virus-infected natural killer lymphocytes in a patient with hypersensitivity to mosquito bites. J Am Acad Dermatol 2005; 53:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/27\">",
"      Cho JH, Kim HS, Ko YH, Park CS. Epstein-Barr virus infected natural killer cell lymphoma in a patient with hypersensitivity to mosquito bite. J Infect 2006; 52:e173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/28\">",
"      McCormack DR, Salata KF, Hershey JN, Carpenter GH. Mosquito anaphylaxis: Hyposensitization with whole body extracts. J Allergy Clin Immunol 1994; 93:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/29\">",
"      Peng Z, Beckett AN, Engler RJ, et al. Immune responses to mosquito saliva in 14 individuals with acute systemic allergic reactions to mosquito bites. J Allergy Clin Immunol 2004; 114:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/30\">",
"      Simons FE, Peng Z. Mosquito allergy: recombinant mosquito salivary antigens for new diagnostic tests. Int Arch Allergy Immunol 2001; 124:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/31\">",
"      Palosuo T, Brummer-Korvenkontio H, Lappalainen P, Reunala T. Immune response to mosquito bites: Characterization of mosquito saliva specific antigens and antibodies by immunoblot technique. J Allergy Clin Immunol 1991; 87:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/32\">",
"      Fradin MS. Mosquitoes and mosquito repellents: a clinician's guide. Ann Intern Med 1998; 128:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/33\">",
"      Moneret-Vautrin DA, Beaudouin E, Kanny G, et al. Anaphylactic shock caused by ticks (Ixodes ricinus). J Allergy Clin Immunol 1998; 101:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/34\">",
"      Gauci M, Loh RK, Stone BF, Thong YH. Allergic reactions to the Australian paralysis tick, Ixodes holocyclus: diagnostic evaluation by skin test and radioimmunoassay. Clin Exp Allergy 1989; 19:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/35\">",
"      Kleine-Tebbe J, Heinatz A, Gr&auml;ser I, et al. Bites of the European pigeon tick (Argas reflexus): Risk of IgE-mediated sensitizations and anaphylactic reactions. J Allergy Clin Immunol 2006; 117:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/36\">",
"      Hilger C, Bessot JC, Hutt N, et al. IgE-mediated anaphylaxis caused by bites of the pigeon tick Argas reflexus: cloning and expression of the major allergen Arg r 1. J Allergy Clin Immunol 2005; 115:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/37\">",
"      Commins SP, James HR, Kelly LA, et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-&alpha;-1,3-galactose. J Allergy Clin Immunol 2011; 127:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/38\">",
"      Hemmer W, Focke M, Vieluf D, et al. Anaphylaxis induced by horsefly bites: identification of a 69 kd IgE-binding salivary gland protein from Chrysops spp. (Diptera, Tabanidae) by western blot analysis. J Allergy Clin Immunol 1998; 101:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/39\">",
"      Naimer SA, Cohen AD, Mumcuoglu KY, Vardy DA. Household papular urticaria. Isr Med Assoc J 2002; 4:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/40\">",
"      Cu&eacute;llar A, Rodr&iacute;guez A, Halpert E, et al. Specific pattern of flea antigen recognition by IgG subclass and IgE during the progression of papular urticaria caused by flea bite. Allergol Immunopathol (Madr) 2010; 38:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/41\">",
"      Bitam I, Dittmar K, Parola P, et al. Fleas and flea-borne diseases. Int J Infect Dis 2010; 14:e667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/42\">",
"      Rust MK. Advances in the control of Ctenocephalides felis (cat flea) on cats and dogs. Trends Parasitol 2005; 21:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/43\">",
"      Dryden MW. Flea and tick control in the 21st century: challenges and opportunities. Vet Dermatol 2009; 20:435.",
"     </a>",
"    </li>",
"    <li>",
"     University of Florida Institute of Food and Agricultural Sciences, Department of Entomology and Nematology. file://entomology.ifas.ufl.edu/creatures.aquatic/biting_midges.htm (Accessed on September 26, 2011).",
"    </li>",
"    <li>",
"     Hill CA, MacDonald JF. Biting midges: biology and public health risk. Purdue University, Department of Entomology. file://extension.entm.purdue.edu/publichealth/insects/bitingmidge.html (Accessed on September 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/46\">",
"      Chen YH, Lee MF, Lan JL, et al. Hypersensitivity to Forcipomyia taiwana (biting midge): clinical analysis and identification of major For t 1, For t 2 and For t 3 allergens. Allergy 2005; 60:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28216/abstract/47\">",
"      Chen YH, Hwang GY, Chen PC, et al. Molecular cloning and immunologic characterization of for t 2: a major allergen from the biting midge Forcipomyia taiwana. Allergy 2011; 66:703.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4088 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28216=[""].join("\n");
var outline_f27_35_28216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Local reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H514913\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Papular urticaria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H514948\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Systemic allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H514983\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SPECIFIC ARTHROPOD BITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mosquitoes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Local reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1284671\">",
"      Allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1284678\">",
"      Other systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H514639\">",
"      - Disease transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ticks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Flies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H514823\">",
"      - Disease transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fleas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17788716\">",
"      Biting midges (no-see-ums)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H762114\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/4088\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4088|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/4/35919\" title=\"picture 1\">",
"      Papular urticaria 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/6/28783\" title=\"picture 2\">",
"      Papular urticaria 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/13/14558\" title=\"picture 3\">",
"      Ixodes scapularis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/25/27038\" title=\"picture 4\">",
"      Ixodes pacificus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/57/20383\" title=\"picture 5\">",
"      American dog tick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/18/21806\" title=\"picture 6\">",
"      Rocky mountain wood tick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/1/23582\" title=\"picture 7\">",
"      Lone star tick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/11/9396\" title=\"picture 8\">",
"      Flea bites thigh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/63/14321\" title=\"picture 9\">",
"      Flea bites ankle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/30/38371\" title=\"picture 10A\">",
"      Staphylococcal folliculitis on leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/30/488\" title=\"picture 10B\">",
"      Folliculitis in dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/60/42946\" title=\"picture 11\">",
"      Lymphomatoid papulosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/29/9685\" title=\"picture 12\">",
"      Pityriasis lichenoides et varioliformis acuta",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36072?source=related_link\">",
"      Allergy to meats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=related_link\">",
"      Approach to the patient with a suspected spider bite: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=related_link\">",
"      Arthropod-borne encephalitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26503?source=related_link\">",
"      Bartonellosis: Oroya fever and verruga peruana",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39286?source=related_link\">",
"      Bedbugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=related_link\">",
"      Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31364?source=related_link\">",
"      Biology of Rickettsia rickettsii infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24248?source=related_link\">",
"      Bites of recluse spiders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25081?source=related_link\">",
"      Bites of widow spiders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43556?source=related_link\">",
"      Chigger bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15576?source=related_link\">",
"      Chikungunya fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36583?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Bartonella quintana infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=related_link\">",
"      Clinical manifestations and diagnosis of cutaneous leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39321?source=related_link\">",
"      Clinical manifestations, diagnosis, treatment, and prevention of babesiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=related_link\">",
"      Clinical presentation and diagnosis of dengue virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/4/3145?source=related_link\">",
"      Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=related_link\">",
"      Diagnosis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/20/42308?source=related_link\">",
"      Epidemiology and control of visceral leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=related_link\">",
"      Evaluation of a tick bite for possible Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22387?source=related_link\">",
"      Folliculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=related_link\">",
"      Human ehrlichiosis and anaplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41766?source=related_link\">",
"      Large local reactions to mosquito bites (Skeeter Syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=related_link\">",
"      Loiasis (Loa loa infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=related_link\">",
"      Lymphomatoid papulosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=related_link\">",
"      Methamphetamine intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23011?source=related_link\">",
"      Mosquito vectors of infectious diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20970?source=related_link\">",
"      Onchocerciasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=related_link\">",
"      Pathogenic Escherichia coli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/22/18786?source=related_link\">",
"      Patient information: Bee and insect stings (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=related_link\">",
"      Patient information: Insect bites and stings (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17369?source=related_link\">",
"      Pityriasis lichenoides et varioliformis acuta (PLEVA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36615?source=related_link\">",
"      Reactions to bites from kissing bugs (Triatoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20152?source=related_link\">",
"      Skin lesions in the returning traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7994?source=related_link\">",
"      Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27796?source=related_link\">",
"      The epidemiology and clinical manifestations of murine typhus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15705?source=related_link\">",
"      Yellow fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_35_28217="Coronary heart disease and myocardial infarction in young men and women";
var content_f27_35_28217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronary heart disease and myocardial infarction in young men and women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/35/28217/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28217/contributors\">",
"     Rabih R Azar, MD, MSc, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/35/28217/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28217/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/35/28217/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28217/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/35/28217/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although coronary heart disease (CHD) primarily occurs in patients over the age of 40, younger men and women can be affected. Most studies have used an age cut-off of 40 to 45 years to define \"young\" patients with CHD or acute myocardial infarction (MI). The same age definition will be used in this review.",
"   </p>",
"   <p>",
"    The prevalence of CHD in younger subjects is difficult to establish accurately since it is frequently a silent process. The frequency with which this occurs was examined in an autopsy study of 760 young (age 15 to 34 years) victims of accidents, suicides, or homicides [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/1\">",
"     1",
"    </a>",
"    ]. Advanced coronary atheromata were seen in 2 percent of men and no women aged 15 to 19. An advanced lesion was present in 20 and 8 percent of men and women aged 30 to 34, respectively, while 19 and 8 percent, respectively, had a &ge;40 percent stenosis of the left anterior descending artery.",
"   </p>",
"   <p>",
"    There are also limited data on the frequency of MI in younger subjects. In the Framingham Heart Study, the incidence of an MI over a 10-year follow-up was",
"    <span class=\"nowrap\">",
"     12.9/1000",
"    </span>",
"    in men 30 to 34 years old and",
"    <span class=\"nowrap\">",
"     5.2/1000",
"    </span>",
"    in women 35 to 44 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence of MI was eight to nine times greater in men and women aged 55 to 64 years. In other studies, 4 to 10 percent of patients with MI were &le;40 or 45 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In two series of patients with CHD at &le;40 years of age, women comprised 5.6 and 11.4 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/3,6\">",
"     3,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although CHD is an uncommon entity in young patients, it constitutes an important problem for the patient and the treating physician because of the devastating effect of this disease on the more active lifestyle of young patients. In addition, these patients have different risk factor profiles, clinical presentations, and prognoses than older patients. All of these factors should be taken into consideration when treating young patients with CHD.",
"   </p>",
"   <p>",
"    A separate issue, acute MI during pregnancy, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30950?source=see_link\">",
"     \"Acute coronary syndromes in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CORONARY RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative importance of risk factors for the development of CHD according to age was evaluated in a report in which 11,016 men aged 18 to 39 years were followed for 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/7\">",
"     7",
"    </a>",
"    ]. The relative risks associated with the traditional risk factors were of similar magnitude as in a group of 8955 men aged 40 to 59 years. These included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &mdash; relative risk 1.63 per six year increase",
"     </li>",
"     <li>",
"      Serum cholesterol &mdash; relative risk 1.92 per 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.04",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      increase",
"     </li>",
"     <li>",
"      Systolic blood pressure &mdash; relative risk 1.32 per 20 mmHg increase",
"     </li>",
"     <li>",
"      Cigarette smoking &mdash; relative risk 1.36 per 10",
"      <span class=\"nowrap\">",
"       cigarette/day",
"      </span>",
"      increase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Young patients with MI usually have multiple risk factors for CHD. In some studies, for example, as many as 90 to 97 percent had one or more traditional risk factors for atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In a prospective study of over 7000 women of mean age 27 years at baseline followed for an average of 31 years, there were 47 CHD deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/11\">",
"     11",
"    </a>",
"    ]. The CHD mortality rates for those with no risk factors, only one risk factor, or two or more risk factors were 0.7, 2.4, and 5.4 per 1000 person-years, respectively. A comparable relationship was seen for cardiovascular disease mortality and for all-cause mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is the most common and most modifiable risk factor in young patients. It has been noted in 65 to 92 percent of young patients with MI, compared to 24 to 56 percent of patients older than 45 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/6,9,12-16\">",
"     6,9,12-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Younger patients with CHD more often have a family history of premature CHD: 41 compared to 28 and 12 percent in middle aged or elderly patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/9\">",
"     9",
"    </a>",
"    ]; and 57 versus 43 percent in two series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/12\">",
"     12",
"    </a>",
"    ]. A higher incidence of a positive family history in young patients (64 percent) was noted in the largest report of 823 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the offspring of patients with premature CHD are more likely to have coronary risk factors than those without such a family history [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/17\">",
"     17",
"    </a>",
"    ]. These include excess body weight and higher levels of serum cholesterol, glucose, and insulin. These offspring are also more likely to have evidence of vascular disease such as endothelial dysfunction and increased carotid artery intima-media thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between family history and premature CHD can be due to both genetic and environmental factors. This was addressed in a study of 398 families in which 62 vascular biology genes were evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/19\">",
"     19",
"    </a>",
"    ]. Missense variants of several thrombospondin genes were significantly associated with MI and CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lipid abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercholesterolemia is common in young patients with CHD, but its prevalence is similar to that in older patients. However, when compared to older patients, young patients have lower mean serum high density lipoprotein (HDL) concentrations (35 versus 43",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.9 versus 1.1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and higher serum triglycerides (239 versus 186",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.7 versus 2.1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertriglyceridemia was, in one series, the most common lipid abnormality in young patients with MI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/20\">",
"     20",
"    </a>",
"    ]. It may be associated with glucose intolerance and a predominance of small atherogenic LDL particles, both of which predispose to atherosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diabetes and hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two other important coronary risk factors, diabetes mellitus and hypertension, appear to be less common in young patients with CHD than in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/6,12\">",
"     6,12",
"    </a>",
"    ]. However, young patients frequently have subtle problems with glucose metabolism. In one study of 108 patients without a history of diabetes mellitus who had an MI before the age of 45, 65 percent had decreased oral glucose tolerance and a hyperinsulinemic response to oral glucose challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/20\">",
"     20",
"    </a>",
"    ]. This finding is consistent with other observations that impaired glucose tolerance in the absence of overt diabetes is a risk factor for coronary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link&amp;anchor=H9#H9\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'CHD before diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity appears to be an independent risk factor for coronary atherosclerosis, at least in young men. This was illustrated in an autopsy study of approximately 3000 persons between the ages of 15 and 34 who died from noncardiac causes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/21\">",
"     21",
"    </a>",
"    ]. Increasing body mass index was associated with both fatty streaks and raised atherosclerotic lesions in the right coronary and left anterior descending coronary arteries in young men, but not young women. The effect of obesity on other risk factors (eg, lipid abnormalities, hypertension, glucose intolerance) accounted for only about 15 percent of the relationship between obesity and coronary atherosclerosis.",
"   </p>",
"   <p>",
"    How this might occur is not known, but other studies have noted an apparently independent effect of obesity as an important coronary risk factor. A report from the Framingham Heart Study suggested that obesity in middle-aged subjects could account for as much as 23 percent of cases of CHD in men and 15 percent in women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Paradoxical embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paradoxical embolism, primarily through a patent foramen ovale, is a rare of myocardial infarction in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=see_link\">",
"     \"Patent foramen ovale\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other possible contributing factors have been identified in young patients with MI. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral contraceptive use in young women, primarily when combined with heavy smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Frequent cocaine use, which, in the Third National Health and Nutrition Examination Survey of 10,085 adults between the ages of 18 and 45, accounted for 25 percent of nonfatal MIs [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link&amp;anchor=H6#H6\">",
"       \"Evaluation and management of the cardiovascular complications of cocaine abuse\", section on 'Myocardial infarction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smoking marijuana may be a rare trigger of MI [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=see_link\">",
"       \"Cannabis use disorders: Treatment, prognosis, and long-term medical effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Factor V Leiden, which is inactivated less efficiently by activated protein C than wild-type factor V, leads to a procoagulant state by increasing thrombin generation. In a report of 107 patients with premature MI but no significant coronary artery stenosis (average age 44), the prevalence of carriers for factor V Leiden was significantly higher in these patients compared to 244 with an MI and significant stenoses and 400 healthy controls (12 versus 4.5 and 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/28\">",
"       28",
"      </a>",
"      ]. At least in young women, the increase in risk with factor V Leiden may be confined to smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"       \"Activated protein C resistance and factor V Leiden\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psychosocial factors, such as anger, may be important in the development of premature CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25528?source=see_link\">",
"       \"Psychosocial factors in coronary and cerebral vascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In women, acute MI may be more common during the follicular phase of the menstrual cycle, a time of relative hypoestrogenemia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=see_link\">",
"       \"Physiology of the normal menstrual cycle\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Risk factors in childhood",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the influence of cardiovascular risk factors in childhood on the development of CHD in later life. The limited data supporting such a correlation are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link&amp;anchor=H4873728#H4873728\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Risk factors in childhood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who develop Kawasaki disease (KD) in childhood (usually before the age of five) are at risk of developing coronary artery aneurysms and stenoses. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Kawasaki disease'",
"    </a>",
"    below.) It is not known whether KD is a risk factor for the development of atherosclerotic coronary disease, although intimal abnormalities have been found in sites remote from the coronary aneurysms in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of CHD in younger patients is different from that in older patients. A higher proportion of young patients do not experience angina [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/4\">",
"     4",
"    </a>",
"    ], and, in the majority of cases, an acute coronary syndrome that progresses rapidly to MI (most often an ST elevation MI) if left untreated is the first manifestation of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/3,15,35\">",
"     3,15,35",
"    </a>",
"    ]. These relationships were illustrated in a series of 200 patients with CHD documented by angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients &le;45 years of age had a lower incidence of stable angina than patients &ge;60 years of age (24 versus 51 percent) and a higher incidence of acute coronary syndromes (76 versus 49 percent). A greater likelihood of complex lesions on arteriography may have contributed to the development of an acute coronary syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar findings were noted in another report of 85 patients less than 40 years of age who were referred for cardiac catheterization and angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/35\">",
"     35",
"    </a>",
"    ]. The first manifestation of CHD was angina in 14 percent and acute MI in 69 percent, two-thirds of whom denied chest pain prior to the infarct. Among those who have preceding chest pain, the first episodes often occur only in the week prior to MI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Establishing the diagnosis of an acute MI is based upon the typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) in biochemical markers of myocardial necrosis with at least one of the following: ischemic symptoms; development of pathologic Q waves on the electrocardiogram (ECG); or ECG changes indicative of ischemia (ST segment elevation or depression). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A potential diagnostic problem that is most common in younger subjects is that myocarditis can mimic an acute MI. This disorder should be particularly considered in young patients with a clinical presentation of an acute coronary syndrome who have a normal coronary angiogram [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In one study of 45 such patients, 35 (78 percent) had a diffuse or focal myocarditis on myocardial imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/36\">",
"     36",
"    </a>",
"    ]. Complete recovery of left ventricular function occurred at six months in 81 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANGIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of patients younger than 45 years of age, angiographic studies were performed because of a history of MI. As expected, major differences were found when compared to older patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Coronary disease severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Younger patients have a higher incidence of normal coronary arteries, mild luminal irregularities, and single vessel coronary artery disease than do older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/10,12,13,15,38\">",
"     10,12,13,15,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest reports of angiographic findings in young patients with CHD comes from a substudy of the CASS trial, which compared the results of coronary angiography in 504 young men (&le;35 years of age) and women (&le;45 years of age) with a history of an MI to those in over 8300 older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/12\">",
"     12",
"    </a>",
"    ]. The following significant differences were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal coronary arteries were more common in the young patients (18 versus 3 percent). Young women had a higher frequency of angiographically normal coronary arteries than young men, despite a 10 year age difference in the definition of \"young.\"",
"     </li>",
"     <li>",
"      Single vessel coronary disease was more common (38 versus 24 percent) and three vessel disease was less common (14 versus 39 percent) in the younger patients.",
"     </li>",
"     <li>",
"      Although some series have shown a predilection for involvement of the left anterior descending artery in young patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/13,38\">",
"       13,38",
"      </a>",
"      ], this was not found in the CASS substudy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another large series of 823 young patients with CHD, single vessel disease was present in 55 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Spontaneous coronary dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous coronary artery dissection is a rare cause of acute MI that is more common in younger patients (under age 50) and in women. In women, the risk of spontaneous coronary dissection appears to be increased during the peripartum period. This disorder is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41113?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features and diagnosis of coronary heart disease in women\", section on 'Spontaneous coronary artery dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Kawasaki disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kawasaki disease (KD) is a vasculitis of infancy and early childhood. It typically presents as an acute febrile illness in children under the age of five; the incidence is higher in Asian and Asian-American populations than in other groups. The etiology of KD is unknown, although an inflammatory response precipitated by an infectious agent is suggested by some epidemiologic data. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11575?source=see_link\">",
"     \"Kawasaki disease: Epidemiology and etiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most important complication of KD is coronary vasculitis, leading to coronary aneurysm formation in 20 to 25 percent of untreated patients during the acute stage of the disease. Nearly half of acute aneurysms regress, but approximately 20 percent lead to the development of coronary stenosis in the long term. Patients can present with MI or SCD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While patients with known KD are followed for the development of coronary artery stenoses, some patients who were not previously diagnosed are recognized only after presenting with sequelae of CHD, including MI, heart failure, and SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Thus, young patients with MI should be asked about a possible childhood history of KD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Normal coronary arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of significant coronary disease is lower in women presenting with chest pain than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. This was illustrated in a report of 886 patients referred for angiographic evaluation of presumed angina, 23 percent of whom were women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/41\">",
"     41",
"    </a>",
"    ]. Normal coronary arteries were much more common in women (41 versus 8 percent in men). Myocardial ischemia is present in a minority of the women with normal coronary arteries (20 percent in two reports), perhaps due to microvascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5802?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ACUTE MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of a young patient with an acute MI varies with type: ST elevation (Q wave) or non-ST elevation (non-Q wave). The overall approach to therapy in these disorders is discussed elsewhere and is generally not dependent upon age. The following discussion will emphasize the issues of reperfusion with primary PCI or thrombolysis and revascularization in young patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factor reduction plays a central role in survivors of the MI. This includes smoking cessation; aggressive lipid lowering, and, in appropriate patients, treatment of diabetes and hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     ST elevation MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young patients with an acute ST elevation MI should be treated with primary PCI or, if not available, thrombolytic therapy. Prospective randomized trials assessing primary PCI and thrombolytic therapy for an acute ST elevation MI have observed that both young and old patients have a better outcome with PCI than thrombolysis. However, young patients do better than older patients regardless of the therapy received. In the GUSTO-IIb trial, for example, the outcome was improved with PCI compared with thrombolytic therapy for each 10-year patient group [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/45\">",
"     45",
"    </a>",
"    ]. Irrespective of treatment, the risk increased with age; after adjusting for baseline characteristics, each increment of 10 years of age increased the risk of death or reinfarction by 1.32. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although data are limited, young patients also appear to respond well to thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/8,46\">",
"     8,46",
"    </a>",
"    ]. In one study, for example, the clinical response to streptokinase, as measured by TIMI II or III flow in the infarct-related artery, was similar in patients &le;35 and &ge;55 years of age (74 versus 73 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Non-ST elevation ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a non-ST elevation acute coronary syndrome (non-ST elevation (non-Q wave) MI or unstable angina) are first stabilized with medical therapy and should undergo early coronary angiography and revascularization, if appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of this early invasive strategy in patients under age 40 is uncertain since few such patients were included in the large clinical trials. Many cardiologists feel obligated to refer these patients for coronary angiography given their \"young age\" and the \"need to know the coronary anatomy.\" However, the observation that some young patients have normal coronary arteries (18 percent in the CASS trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/12\">",
"     12",
"    </a>",
"    ]) or nonobstructive coronary disease does not justify the routine use of this approach. An exercise stress test is a simpler and more cost-effective modality to risk stratify young patients with CHD and an MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of this approach is illustrated by the following observations. One report evaluated 129 patients under 40 years of age who had coronary angiography within 60 days of their first acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/47\">",
"     47",
"    </a>",
"    ]. Patients without evidence of spontaneous or induced ischemia were compared to those who had ischemia or abnormal stress test after the MI; the two groups were similar with regard to all clinical variables.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the patients without evidence of ischemia, the coronary arteries were normal in 23 percent, single or multivessel disease was present in 60 and 16 percent, respectively, and no patient had left main disease. None of these patients underwent PCI or CABG and, after a 77 month follow-up, the cardiac mortality was 5 percent.",
"     </li>",
"     <li>",
"      The patients with documented ischemia were more likely to have extensive CHD (36 percent had multivessel disease, and 4 percent had left main disease) and less likely to have no or one-vessel disease (11 and 49 percent, respectively). The revascularization rate in this group was 41 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A smaller study also found that exercise testing in the young patient who is asymptomatic after an MI is an effective technique to identify a low risk group [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/13\">",
"     13",
"    </a>",
"    ]. No surgically correctable disease was found in 19 patients who underwent cardiac catheterization for prognosis and were able to reach at least stage 4 on a Bruce protocol exercise test.",
"   </p>",
"   <p>",
"    Based upon these data, we recommend early coronary angiography only for young patients with high-risk features such as recurrent ischemia or multiple risk factors. Many other lower-risk patients with an uncomplicated course can undergo exercise stress testing for risk stratification before discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS AFTER MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction occurring at an early age raises the disturbing potential of a malignant atherosclerotic diathesis and an adverse prognosis. However, as noted above, many such patients do not have severe coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/12,47\">",
"     12,47",
"    </a>",
"    ] and most series have noted both a favorable short- and long-term prognosis in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     In-hospital mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The in-hospital mortality in young patients has ranged from 0 to 4 percent, a value lower than that in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/3,9,46,48\">",
"     3,9,46,48",
"    </a>",
"    ]. This was illustrated in a review of 2643 patients with an acute MI: the in-hospital mortality for those aged &le;45 years, 46 to 70 years, and &gt;70 years was 2.5, 9, and 21 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/9\">",
"     9",
"    </a>",
"    ]. Virtually identical rates were noted in a review from the GISSI-2 database of patients with an ST elevation MI treated with thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young patients also have a good long-term outcome after MI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/6,12,49\">",
"     6,12,49",
"    </a>",
"    ]. In the large CASS trial substudy mentioned above, survival rates at seven years after an MI were 84 versus 75 percent for young and older men and 90 versus 77 percent for young and older women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/12\">",
"     12",
"    </a>",
"    ]. The cause of death was cardiovascular in 84 percent of patients, a finding that was not affected by age or gender. After adjusting for more favorable baseline characteristics in younger patients, there was no difference in the rate of reinfarction between younger and older men (18 versus 20 percent) or younger and older women (15 versus 21 percent).",
"   </p>",
"   <p>",
"    Longer-term data were provided by a second study of 823 patients with CHD, 55 percent of whom had a prior MI and 10 percent of whom had diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/6\">",
"     6",
"    </a>",
"    ]. Mortality at 15 years was 30 percent overall, but markedly increased in those with prior MI (45 percent), diabetes (65 percent), and left ventricular ejection fraction less than 30 percent (83 percent). The number of diseased vessels in this and another report [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/49\">",
"     49",
"    </a>",
"    ] was not predictive of outcome, because patients with more severe disease were more likely to undergo revascularization. In the latter study, 17-year mortality was only 9 percent in patients with normal coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the mortality risk, recurrent coronary events are not uncommon. This was illustrated in a report of 108 nondiabetic men &le;45 years of age followed for six to nine years after an acute MI; the event rate (death, acute MI, coronary revascularization) of 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In multivariate models, predictors of long-term mortality or reinfarction in addition to prior MI, diabetes, and low ejection fraction have included atrial fibrillation, use of antiarrhythmic drugs, continued smoking, and the plasma PAI-1 concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/6,9,20\">",
"     6,9,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF CHRONIC CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of stable angina, including the indications for revascularization, is similar in younger and older patients. Routine coronary angiography is not recommended in young patients who have stable CHD. However, when indicated, both PCI and CABG are effective and are associated with lower risks in younger compared to older patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management should also include intensive risk factor reduction including smoking cessation, initiation of an exercise program, aggressive lipid lowering, screening for depression, and, in appropriate patients, treatment of diabetes and hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Percutaneous intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome of young patients undergoing percutaneous coronary intervention (PCI) is quite good [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/6,50,51\">",
"     6,50,51",
"    </a>",
"    ]. In a study that assessed the outcome of PCI in 140 consecutive patients &le;40 years of age, the acute success rate was 93 percent with a 28 percent rate of angiographic restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/50\">",
"     50",
"    </a>",
"    ]. Ten-year overall and event-free survival (without MI, elective CABG, or repeat PCI) following PCI were 96 and 58 percent, respectively. Among survivors, 88 percent were free of angina, 93 percent had returned to work, and 19 percent underwent a repeat revascularization procedure because of disease progression at other sites or restenosis.",
"   </p>",
"   <p>",
"    A second report compared the outcome of PCI in 89 patients &le;40 years of age with that of 1916 patients over 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/51\">",
"     51",
"    </a>",
"    ]. Procedural success was similar in the young and older patients (90 versus 86 percent); there were no periprocedural complications in the younger group, while 7 percent of patients in the older group had a cardiac event (death, MI, or urgent CABG). After a mean follow-up of 30 months, there were no deaths; however, 5 percent required elective CABG and 34 percent underwent repeat PCI for restenosis or disease progression.",
"   </p>",
"   <p>",
"    The applicability of these findings on repeat revascularization, published in 1994, to current practice is uncertain. Advances such as coronary artery stenting, particularly drug-eluting stents and more aggressive antiplatelet therapy have reduced the risk of restenosis, while aggressive lipid lowering with statin therapy may reduce the risk of disease progression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Bypass surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery bypass grafting (CABG) is easier to perform in young patients because they are usually in better physical condition than older patients and can better tolerate the stress of surgery and general anesthesia. One report reviewed the data on 138 patients less than 40 years of age who underwent CABG with a saphenous vein graft, primarily for angina [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/52\">",
"     52",
"    </a>",
"    ]. More than one-half had a prior MI, 60 percent had three-vessel coronary artery disease, and 42 percent had serious left ventricular dysfunction. There was no operative mortality, and the rate of perioperative transmural acute MI was 4 percent. Survival rates at five and ten years were 95 and 84 percent, respectively. There was no significant difference between the long-term patency rate of the saphenous vein grafts compared with other series that included older age groups.",
"   </p>",
"   <p>",
"    Similar results were noted in another study of 107 patients &le;35 years of age in whom the actuarial survival at five and ten years was 94 and 85 percent, respectively, and the actuarial event-free survival was 77 and 53 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/53\">",
"     53",
"    </a>",
"    ]. Survival was decreased by multivessel disease and impaired left ventricular function, and event-free survival was decreased by a family history of coronary disease and cigarette smoking. The long-term patency was much higher with mammary artery grafts (93 versus 56 percent with saphenous vein grafts).",
"   </p>",
"   <p>",
"    Better long-term patency with arterial grafts has been noted in other studies in young patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28217/abstract/54\">",
"     54",
"    </a>",
"    ] and is well described in older patients. Arterial grafts are now preferred in all patients undergoing CABG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H386462426\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic coronary heart disease (CHD) is uncommon in young men and women (age less than 40 to 45 years). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Younger patients with CHD more often have a family history of premature CHD. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Family history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cigarette smoking is the most common and most modifiable risk factor in young patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Smoking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diabetes mellitus and hypertension appear to be less common in young patients with CHD than in older patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diabetes and hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other risk factors such as cocaine use, factor V Leiden, and oral contraceptive use are more common in younger individuals with CHD. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Other factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of CHD in younger patients is different from that in older patients. A higher proportion of young patients do not experience angina, and, in the majority of cases, an acute coronary syndrome that progresses rapidly to MI if left untreated is the first manifestation of CHD. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Younger patients have a higher incidence of normal coronary arteries, mild luminal irregularities, and single vessel coronary artery disease than do older patients. Rarer causes of CHD such as spontaneous coronary dissection or Kawasaki disease occur more commonly in the young. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Angiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the management of CHD in the young is similar to that in older individuals. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Management of chronic CHD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/1\">",
"      McGill HC Jr, McMahan CA, Zieske AW, et al. Association of Coronary Heart Disease Risk Factors with microscopic qualities of coronary atherosclerosis in youth. Circulation 2000; 102:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/2\">",
"      Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med 1984; 311:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/3\">",
"      Fournier JA, S&aacute;nchez A, Quero J, et al. Myocardial infarction in men aged 40 years or less: a prospective clinical-angiographic study. Clin Cardiol 1996; 19:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/4\">",
"      Doughty M, Mehta R, Bruckman D, et al. Acute myocardial infarction in the young--The University of Michigan experience. Am Heart J 2002; 143:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/5\">",
"      Greenland P, Reicher-Reiss H, Goldbourt U, Behar S. In-hospital and 1-year mortality in 1,524 women after myocardial infarction. Comparison with 4,315 men. Circulation 1991; 83:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/6\">",
"      Cole JH, Miller JI 3rd, Sperling LS, Weintraub WS. Long-term follow-up of coronary artery disease presenting in young adults. J Am Coll Cardiol 2003; 41:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/7\">",
"      Navas-Nacher EL, Colangelo L, Beam C, Greenland P. Risk factors for coronary heart disease in men 18 to 39 years of age. Ann Intern Med 2001; 134:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/8\">",
"      Chouhan L, Hajar HA, Pomposiello JC. Comparison of thrombolytic therapy for acute myocardial infarction in patients aged &lt; 35 and &gt; 55 years. Am J Cardiol 1993; 71:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/9\">",
"      Hoit BD, Gilpin EA, Henning H, et al. Myocardial infarction in young patients: an analysis by age subsets. Circulation 1986; 74:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/10\">",
"      al-Koubaisy OK, Mehdi RS, Arem FD, Ahmed IT. Cine angiographic findings in young Iraqi men with first acute myocardial infarction. Cathet Cardiovasc Diagn 1990; 19:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/11\">",
"      Daviglus ML, Stamler J, Pirzada A, et al. Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. JAMA 2004; 292:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/12\">",
"      Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 1995; 26:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/13\">",
"      Wolfe MW, Vacek JL. Myocardial infarction in the young. Angiographic features and risk factor analysis of patients with myocardial infarction at or before the age of 35 years. Chest 1988; 94:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/14\">",
"      Barbash GI, White HD, Modan M, et al. Acute myocardial infarction in the young--the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Eur Heart J 1995; 16:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/15\">",
"      Chen L, Chester M, Kaski JC. Clinical factors and angiographic features associated with premature coronary artery disease. Chest 1995; 108:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/16\">",
"      Rosenberg L, Kaufman DW, Helmrich SP, et al. Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA 1985; 253:2965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/17\">",
"      Bao W, Srinivasan SR, Wattigney WA, Berenson GS. The relation of parental cardiovascular disease to risk factors in children and young adults. The Bogalusa Heart Study. Circulation 1995; 91:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/18\">",
"      Gaeta G, De Michele M, Cuomo S, et al. Arterial abnormalities in the offspring of patients with premature myocardial infarction. N Engl J Med 2000; 343:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/19\">",
"      Topol EJ, McCarthy J, Gabriel S, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001; 104:2641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/20\">",
"      Malmberg K, B&aring;venholm P, Hamsten A. Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age. J Am Coll Cardiol 1994; 24:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/21\">",
"      McGill HC Jr, McMahan CA, Herderick EE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002; 105:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/22\">",
"      Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/23\">",
"      Sastry S, Riding G, Morris J, et al. Young Adult Myocardial Infarction and Ischemic Stroke: the role of paradoxical embolism and thrombophilia (The YAMIS Study). J Am Coll Cardiol 2006; 48:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/24\">",
"      Agostoni P, Gasparini G, Destro G. Acute myocardial infarction probably caused by paradoxical embolus in a pregnant woman. Heart 2004; 90:e12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/25\">",
"      Rosenberg L, Palmer JR, Rao RS, Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 2001; 161:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/26\">",
"      Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. Circulation 2001; 103:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/27\">",
"      Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation 2001; 103:2805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/28\">",
"      Mansourati J, Da Costa A, Munier S, et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000; 83:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/29\">",
"      Tanis BC, Bloemenkamp DG, van den Bosch MA, et al. Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction. Br J Haematol 2003; 122:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/30\">",
"      Chang PP, Ford DE, Meoni LA, et al. Anger in young men and subsequent premature cardiovascular disease: the precursors study. Arch Intern Med 2002; 162:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/31\">",
"      Hamelin BA, M&eacute;thot J, Arsenault M, et al. Influence of the menstrual cycle on the timing of acute coronary events in premenopausal women. Am J Med 2003; 114:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/32\">",
"      Mukamal KJ, Muller JE, Maclure M, et al. Variation in the risk of onset of acute myocardial infarction during the menstrual cycle. Am J Cardiol 2002; 90:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/33\">",
"      Noto N, Okada T, Yamasuge M, et al. Noninvasive assessment of the early progression of atherosclerosis in adolescents with Kawasaki disease and coronary artery lesions. Pediatrics 2001; 107:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/34\">",
"      Takahashi K, Oharaseki T, Naoe S. Pathological study of postcoronary arteritis in adolescents and young adults: with reference to the relationship between sequelae of Kawasaki disease and atherosclerosis. Pediatr Cardiol 2001; 22:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/35\">",
"      Klein LW, Agarwal JB, Herlich MB, et al. Prognosis of symptomatic coronary artery disease in young adults aged 40 years or less. Am J Cardiol 1987; 60:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/36\">",
"      Sarda L, Colin P, Boccara F, et al. Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms. J Am Coll Cardiol 2001; 37:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/37\">",
"      Karjalainen J, Heikkil&auml; J. Incidence of three presentations of acute myocarditis in young men in military service. A 20-year experience. Eur Heart J 1999; 20:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/38\">",
"      Davia JE, Hallal FJ, Cheitlin MD, et al. Coronary artery disease in young patients: arteriographic and clinical review of 40 cases aged 35 and under. Am Heart J 1974; 87:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/39\">",
"      Kato H, Inoue O, Kawasaki T, et al. Adult coronary artery disease probably due to childhood Kawasaki disease. Lancet 1992; 340:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/40\">",
"      Burns JC, Shike H, Gordon JB, et al. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996; 28:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/41\">",
"      Sullivan AK, Holdright DR, Wright CA, et al. Chest pain in women: clinical, investigative, and prognostic features. BMJ 1994; 308:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/42\">",
"      Gurevitz O, Jonas M, Boyko V, et al. Clinical profile and long-term prognosis of women &lt; or = 50 years of age referred for coronary angiography for evaluation of chest pain. Am J Cardiol 2000; 85:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/43\">",
"      Buchthal SD, den Hollander JA, Merz CN, et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 2000; 342:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/44\">",
"      Johnson BD, Shaw LJ, Buchthal SD, et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/45\">",
"      Holmes DR Jr, White HD, Pieper KS, et al. Effect of age on outcome with primary angioplasty versus thrombolysis. J Am Coll Cardiol 1999; 33:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/46\">",
"      Moccetti T, Malacrida R, Pasotti E, et al. Epidemiologic variables and outcome of 1972 young patients with acute myocardial infarction. Data from the GISSI-2 database. Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). Arch Intern Med 1997; 157:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/47\">",
"      Negus BH, Willard JE, Glamann DB, et al. Coronary anatomy and prognosis of young, asymptomatic survivors of myocardial infarction. Am J Med 1994; 96:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/48\">",
"      F&uuml;llhaas JU, Rickenbacher P, Pfisterer M, Ritz R. Long-term prognosis of young patients after myocardial infarction in the thrombolytic era. Clin Cardiol 1997; 20:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/49\">",
"      Porter A, Wurzel M, Ben-Gal T, et al. Long-term prognosis of 210 patients who underwent coronary angiography before 40 years of age. Am J Cardiol 1998; 81:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/50\">",
"      Buffet P, Colasante B, Feldmann L, et al. Long-term follow-up after coronary angioplasty in patients younger than 40 years of age. Am Heart J 1994; 127:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/51\">",
"      Mehan VK, Urban P, Dorsaz PA, Meier B. Coronary angioplasty in the young: procedural results and late outcome. J Invasive Cardiol 1994; 6:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/52\">",
"      FitzGibbon GM, Hamilton MG, Leach AJ, et al. Coronary artery disease and coronary bypass grafting in young men: experience with 138 subjects 39 years of age and younger. J Am Coll Cardiol 1987; 9:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/53\">",
"      Lytle BW, Kramer JR, Golding LR, et al. Young adults with coronary atherosclerosis: 10 year results of surgical myocardial revascularization. J Am Coll Cardiol 1984; 4:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28217/abstract/54\">",
"      Ng WK, Vedder M, Whitlock RM, et al. Coronary revascularisation in young adults. Eur J Cardiothorac Surg 1997; 11:732.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 50 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-D52EA7ED9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28217=[""].join("\n");
var outline_f27_35_28217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H386462426\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CORONARY RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lipid abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diabetes and hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Paradoxical embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Risk factors in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANGIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Coronary disease severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Spontaneous coronary dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Normal coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT OF ACUTE MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ST elevation MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Non-ST elevation ACS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS AFTER MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      In-hospital mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MANAGEMENT OF CHRONIC CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Percutaneous intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Bypass surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H386462426\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30950?source=related_link\">",
"      Acute coronary syndromes in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=related_link\">",
"      Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5802?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=related_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41113?source=related_link\">",
"      Clinical features and diagnosis of coronary heart disease in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11575?source=related_link\">",
"      Kawasaki disease: Epidemiology and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=related_link\">",
"      Patent foramen ovale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=related_link\">",
"      Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25528?source=related_link\">",
"      Psychosocial factors in coronary and cerebral vascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_35_28218="Activated protein C resistance and factor V Leiden";
var content_f27_35_28218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Activated protein C resistance and factor V Leiden",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/35/28218/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28218/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/35/28218/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28218/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/35/28218/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/35/28218/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/35/28218/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor V Leiden is the most common cause of inherited thrombophilia in Caucasian populations, accounting for 40 to 50 percent of cases. The prothrombin gene mutation, deficiencies in protein S, protein C, and antithrombin account for most of the remaining cases, while rare causes include the dysfibrinogenemias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The total incidence of an inherited thrombophilia in subjects with a deep vein thrombosis ranges from 24 to 37 percent overall, compared with about 10 percent in controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review will discuss the causes, prevalence, clinical presentation and diagnosis of activated protein C (APC) resistance and factor V Leiden [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/3\">",
"     3",
"    </a>",
"    ]. Screening for, and the general treatment of, the inherited thrombophilias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor V circulates in plasma as an inactive cofactor. Activation by thrombin results in the formation of factor Va, which then serves as a cofactor in the conversion of prothrombin to thrombin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of hemostasis\", section on 'Multicomponent complexes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factor Va is enzymatically inactivated by proteolytic cleavages in its heavy chain. The mechanism of factor Va inactivation is an ordered event. Factor Va is first cleaved at Arg506 and then at Arg306 and Arg679 by activated protein C. The peptide bond cleavage at Arg506 facilitates the exposure of cleavage sites at Arg306 and Arg679 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1993, a group of individuals with unexplained venous thromboembolism were reported whose plasmas exhibited a poor response to activated protein C (APC) in an activated partial thromboplastin time (aPTT) assay. Recognized mechanisms for APC resistance, such as functional protein S deficiency or inhibitors of APC, were excluded. Other clinically affected relatives of the probands demonstrated APC resistance in the aPTT-based test, suggesting that the abnormality was inherited.",
"   </p>",
"   <p>",
"    The molecular basis for the laboratory phenotype of resistance to APC was found to be a mutation in the gene coding for coagulation factor V [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/5\">",
"     5",
"    </a>",
"    ]. A transition (guanine to adenine) at nucleotide 1691 (G1691) resulted in the replacement of arginine at position 506 in factor V by glutamine. The gene product, factor V Leiden (factor V Q506, Arg506Gln) is not susceptible to cleavage at position 506 by activated protein C and is therefore inactivated more slowly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dual defect leading to hypercoagulable state",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factor V Leiden mutation leads to a hypercoagulable state for two reasons, due to the critical position of factor V in both the coagulant and anticoagulant pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of hemostasis\", section on 'Multicomponent complexes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Increased coagulation",
"      </strong>",
"      &mdash; The activated form of Factor V Leiden is inactivated more slowly by APC than is normal Factor Va. Accordingly, more factor Va is available within the prothrombinase complex, increasing coagulation via the increased generation of thrombin.",
"     </li>",
"     <li>",
"      <strong>",
"       Decreased anticoagulation",
"      </strong>",
"      &mdash; Factor V cleaved at position 506 is also thought to be a cofactor, along with protein S, in supporting the role of activated protein C in the degradation of factor VIIIa (in the tenase complex) as well as factor Va (in the prothrombinase complex) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. Lack of this cleavage product in patients with factor V Leiden thus decreases the anticoagulant activity of activated protein C.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The poor susceptibility to cleavage by APC as well as impaired APC cofactor activity appear to contribute equally to the phenomenon of Factor V Leiden-associated APC resistance and the ensuing hypercoagulable state [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dual nature of factor V also helps to explain why the risk of thrombosis is greater in patients homozygous or pseudohomozygous (ie, compound heterozygosity for factor V Leiden and type I factor V deficiency) for factor V Leiden than in heterozygotes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. The blood of heterozygotes, unlike the situation in homozygotes and pseudohomozygotes, contains both factor V Leiden and normal factor V. Presence of the normal factor V molecule allows for the inactivation of factor VIIIa by APC, via the second of the two pathways noted above, affording some protection against thrombosis. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Factor V Leiden plus factor V deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CAUSES AND PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes for APC resistance are genetic or acquired [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic &mdash; Heterozygosity for the factor V Leiden mutation accounts for 90 to 95 percent of cases of the hereditary APC resistance. A much smaller number of homozygotes exist. In rare cases, genetic abnormalities other than the factor V Q506 mutation produce the APC resistance phenotype or modulate its expression in factor V Q506 heterozygotes.",
"     </li>",
"     <li>",
"      Acquired &mdash; Acquired conditions that can cause APC resistance in first generation APC resistance assays include elevated factor VIII levels, pregnancy, use of oral contraceptives, and the presence of antiphospholipid antibodies. Some patients have been described with APC resistance of unknown cause [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Acquired APC resistance'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Heterozygosity for factor V Leiden",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of heterozygosity for the factor V Leiden mutation in Caucasians, including European, Jewish, Israeli, Arab, Canadian and Indian populations, ranges from 1 to 8.5 percent, with most European studies reporting overall rates of 5 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The prevalence has been reported to be approximately 15 percent in some parts of Greece, Sweden, and Lebanon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. On the other hand, the factor V Leiden mutation is apparently not present in African Blacks, Chinese, or Japanese populations.",
"   </p>",
"   <p>",
"    In a study of 4047 American men and women participating in the Physician's Health Study and the Women's Health Study, the following carrier frequencies for factor V Leiden were found [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Caucasians &mdash; 5.3 percent",
"     </li>",
"     <li>",
"      Hispanic Americans &mdash; 2.2 percent",
"     </li>",
"     <li>",
"      Native Americans &mdash; 1.2 percent",
"     </li>",
"     <li>",
"      African Americans &mdash; 1.2 percent",
"     </li>",
"     <li>",
"      Asian Americans &mdash; 0.45 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies using dimorphic sites in the factor V gene to do haplotype analysis have provided evidence for the existence of a founder effect as the basis for the mutation in Caucasians of differing ethnic backgrounds [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/20\">",
"     20",
"    </a>",
"    ]. It has been estimated that the mutation originated approximately 30,000 years ago, after the evolutionary divergence of Caucasian, African, and Oriental populations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/20\">",
"     20",
"    </a>",
"    ]. Similar data, indicating a founder haplotype and a single genetic origin during the same time period, have been found in studies of individuals with the prothrombin mutation, which occurs independently in the same ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=see_link\">",
"     \"Prothrombin gene mutation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Homozygosity for factor V Leiden",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homozygotes account for about 1 percent of patients with the factor V Leiden mutation but are disproportionately represented clinically, as compared with the general population, because of a higher thrombotic risk. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other genetic defects in factor V",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several mutations at the Arg306 residue in factor V, the second APC site cleavage in the activated cofactor, have been described in patients with a history of thrombosis. These include replacement of Arg306 with threonine (factor V Cambridge) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/22\">",
"     22",
"    </a>",
"    ] or with glycine (in Hong Kong Chinese) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/23\">",
"     23",
"    </a>",
"    ]. Thr306, albeit rare, does confer APC resistance. The clinical importance of Gly306 is uncertain, since it may not be associated with APC resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/23\">",
"     23",
"    </a>",
"    ] and the mutation is as common in healthy Chinese blood donors as in patients with thrombosis (4.5 and 4.7 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factor V Liverpool (Ile359Thr) has been associated with an increased risk of thrombosis, apparently due to both reduced APC-mediated inactivation of factor Va as well as being a poor APC cofactor for the inactivation of factor VIIIa [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Physiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     HR2 haplotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above-noted mutations, several polymorphisms are present in the factor V gene [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/26\">",
"     26",
"    </a>",
"    ]. An extended factor V gene haplotype (HR2) containing the R2 polymorphism (Arg1299) is in complete linkage disequilibrium with the factor V Leiden allele and is found with increased frequency in heterozygous factor V Leiden-positive patients with the lowest APC resistance ratios [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The slight increase in thrombotic risk in those with the HR2 haplotype may be due to a reduction in its activated protein C cofactor activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/8\">",
"     8",
"    </a>",
"    ]. However, it is controversial whether the HR2 haplotype is associated with increased thrombotic risk in the absence of factor V Leiden [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/8,28-34\">",
"     8,28-34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Physiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Factor V Leiden plus factor V deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients have been described in whom there is cosegregation of heterozygous APC resistance due to the factor V Leiden mutation along with type I factor V deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. The plasma of these individuals manifests severe APC resistance in activated partial thromboplastin time assays, similar to patients with homozygous factor V Leiden (ie, they are pseudohomozygous). These patients appear to be more thrombosis prone than heterozygous relatives with factor V Leiden alone, suggesting that the clinical phenotype is similar to [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/11,39\">",
"     11,39",
"    </a>",
"    ], or more severe than [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/40\">",
"     40",
"    </a>",
"    ], that of patients homozygous for factor V Leiden.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other genetic influences",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Having a non-O blood group (eg, A, B, or AB) appears to increase the risk of developing VTE in both heterozygotes and homozygotes for factor V Leiden by two- to four-fold [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/41-43\">",
"       41-43",
"      </a>",
"      ]. This may be explained, at least in part, by the higher levels of factor VIII seen in non-O individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/43-45\">",
"       43-45",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Combined inherited defects'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=see_link&amp;anchor=H5#H5\">",
"       \"Biology and normal function of von Willebrand factor\", section on 'Plasma VWF'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Studies in both mouse and man have suggested that alterations in the protein Z gene may influence the clinical symptoms of thromboembolism in patients with factor V Leiden. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/32/20999?source=see_link&amp;anchor=H13#H13\">",
"       \"Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins\", section on 'Protein Z'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Common single nucleotide polymorphisms in the factor V gene may reduce the quantity of normal factor V in individuals heterozygous for factor V Leiden, and increase the risk of venous thromboembolism [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Acquired APC resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with APC resistance without the factor V Leiden mutation can be identified using the first generation aPTT-based assay for APC resistance (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Diagnostic assays'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals with cerebrovascular disease have been described with APC resistance not due to the factor V Leiden mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. In one study, the investigators divided patients into five categories of responsiveness to APC, as opposed to the usual practice of using a cutoff value for optimal separation of carriers and noncarriers of the mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/48\">",
"       48",
"      </a>",
"      ]. Statistical analysis showed that a low response to APC was associated with an increased risk of cerebrovascular disease, which was independent of the factor V Leiden mutation.",
"     </li>",
"     <li>",
"      In the Leiden Thrombophilia Study, a case-control study including 474 patients with a first episode of deep vein thrombosis and 474 age- and sex-matched controls, in which all carriers of the factor V Leiden mutation were excluded, a dose-response relationship was observed between the sensitivity for APC and the risk of thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/13\">",
"       13",
"      </a>",
"      ]. After correcting for confounding variables, a reduced response to APC remained a risk factor for thrombosis (odds ratio for the lowest quartile: 2.5; 95% CI 1.5-4.2).",
"     </li>",
"     <li>",
"      In a study of over 14,000 participants in the Vicenza Thrombophilia and Atherosclerosis Project who did not have factor V Leiden, the adjusted odds ratio for development of VTE was 1.7 (95% CI 1.0-2.7) in those with phenotypic resistance to APC [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Significant resistance to APC has been found in patients with multiple myeloma and other cancers [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/50,51\">",
"       50,51",
"      </a>",
"      ], and may contribute to the thrombotic tendency in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/50,52,53\">",
"       50,52,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Resistance to APC has also been found in some patients with systemic lupus erythematosus and the antiphospholipid antibody syndrome in the absence of factor V Leiden. This subject is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link&amp;anchor=H17#H17\">",
"       \"Pathogenesis of the antiphospholipid syndrome\", section on 'Genetic predisposition'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present, the clinical importance of documenting this type of APC resistance is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. The use of assays to identify these individuals is best restricted to research studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of oral contraceptives (OC), especially third generation OCs, has been associated with acquired APC resistance. APC resistance, which can also be acquired following use of hormone replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/57\">",
"     57",
"    </a>",
"    ], may underlie, in part, the supra-additive effect of exogenous estrogens on thrombotic risk in women with factor V Leiden (",
"    <a class=\"graphic graphic_table graphicRef56252 \" href=\"UTD.htm?21/4/21579\">",
"     table 1",
"    </a>",
"    ), or in those women without factor V Leiden who have the lowest APC resistance ratios [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H11#H11\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Venous thromboembolic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    According to data from the Leiden Thrombophilia Study (",
"    <a class=\"graphic graphic_table graphicRef56252 \" href=\"UTD.htm?21/4/21579\">",
"     table 1",
"    </a>",
"    ), the annual risk of developing a first episode of VTE for patients with varying combinations of factor V Leiden and use of OCs, is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal subjects &mdash; 1 in 12,500",
"     </li>",
"     <li>",
"      Use of OCs &mdash; 1 in 3333",
"     </li>",
"     <li>",
"      Factor V Leiden heterozygotes &mdash; 1 in 1667",
"     </li>",
"     <li>",
"      Factor V Leiden heterozygotes taking OCs &mdash; 1 in 345",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical manifestation of factor V Leiden, the most common cause of hereditary thrombophilia, is deep vein thrombosis with or without pulmonary embolism (ie, venous thromboembolic disease). The mutation is also a risk factor for cerebral, mesenteric, and portal vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Despite the increase in risk of venous thrombosis, there is no evidence that heterozygosity for factor V Leiden increases overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is evidence that the factor V Leiden mutation, presumably due to thrombosis of placental vessels, may play a role in some cases of unexplained recurrent pregnancy loss [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Obstetric complications'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Risk of DVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have evaluated the role of factor V Leiden in the risk of venous thromboembolism (",
"    <a class=\"graphic graphic_table graphicRef56252 \" href=\"UTD.htm?21/4/21579\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/67-73\">",
"     67-73",
"    </a>",
"    ]. Approximately 10 to 26 percent of such patients have this mutation, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Physicians' Health Study found a 12 percent incidence of heterozygosity for the factor V Leiden mutation in patients with a first confirmed deep vein thrombosis (DVT) or pulmonary embolism, compared with 6 percent in controls [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/73\">",
"       73",
"      </a>",
"      ]. The incidence reached 26 percent in 31 men &gt;60 years of age with no identifiable precipitating factors (ie, those with",
"      <span class=\"nowrap\">",
"       idiopathic/unprovoked",
"      </span>",
"      VTE) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Leiden Thrombophilia Study, consisting of 471 patients under age 70 with a first confirmed DVT and 474 healthy controls, found a 21 percent incidence of activated protein C resistance, compared with 5 percent in controls [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. The incidence of heterozygosity (18 versus 3 percent) and homozygosity for factor V Leiden (1.5 versus zero percent) was significantly higher in the patients with thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/71\">",
"       71",
"      </a>",
"      ]. The relative risk for DVT was increased sevenfold for heterozygotes and 80-fold for homozygotes (",
"      <a class=\"graphic graphic_table graphicRef56252 \" href=\"UTD.htm?21/4/21579\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In a study of 306 family members from 50 Swedish families, 40 percent of homozygotes for factor V Leiden had an episode of venous thrombosis by age 33, compared with 20 percent of heterozygotes and 8 percent of normal subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although possibly influenced by a selection bias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/74\">",
"     74",
"    </a>",
"    ], the lifetime probability of developing thrombosis and the severity of the thromboses are considerably less in heterozygotes with the factor V Leiden mutation than in patients with the less common inherited thrombophilias. This was illustrated in a report that compared the risk for thrombosis in individuals with inherited thrombophilia due to factor V Leiden or to antithrombin, protein C, or protein S deficiency in 150 pedigrees [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/75\">",
"     75",
"    </a>",
"    ]. The lifetime probability of developing thrombosis compared with those with no defect was 8.5 times higher for carriers of protein S deficiency, 8.1 for antithrombin deficiency, 7.3 for protein C deficiency, and 2.2 for factor V Leiden. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the increase in thrombotic tendency, the risk of thrombosis in homozygous factor V Leiden is significantly less than the risk in homozygous or doubly heterozygous protein C or protein S deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Combined inherited defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be an increased incidence of factor V Leiden among thrombotic patients with other thrombophilic defects, as compared with the general population. These include deficiencies of protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/76,77\">",
"     76,77",
"    </a>",
"    ], protein S [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/78,79\">",
"     78,79",
"    </a>",
"    ], antithrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/80\">",
"     80",
"    </a>",
"    ], the prothrombin gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/81,82\">",
"     81,82",
"    </a>",
"    ], and elevated levels of factor VIII [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/44\">",
"     44",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 18 unrelated thrombosis-prone families with inherited protein S deficiency found a concomitant factor V gene mutation in 39 percent of the study subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report which compared 113 patients with protein C deficiency and 104 healthy volunteers, the Arg506Gln mutation in factor V was much more common in those with protein C deficiency than in controls (15 versus 1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Carriers of two defects seem to be at a higher risk for thrombosis than their relatives with a single defect. In one review of four studies, approximately 75 percent of the family members who were carriers of two defects had experienced thrombosis compared with 10 to 30 percent of the carriers of a single defect [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/83\">",
"     83",
"    </a>",
"    ]. The presence of two defects in these studies increased the thrombotic risk three-fold above the risk of a single defect.",
"   </p>",
"   <p>",
"    A pooled analysis of eight case-control studies evaluated thrombotic risks in patients bearing factor V Leiden",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the prothrombin G20210A mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/84\">",
"     84",
"    </a>",
"    ]. The following odds ratios for the risk of VTE were found:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Factor V Leiden heterozygotes &mdash; 4.9",
"     </li>",
"     <li>",
"      Prothrombin G20210A mutation heterozygotes &mdash; 3.8",
"     </li>",
"     <li>",
"      Both mutations (ie, double heterozygotes) &mdash; 20.0",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Double heterozygosity occurred in 2.2 percent of patients with VTE overall, in 12 percent of patients who were heterozygous for factor V Leiden, and in 23 percent of patients heterozygous for the prothrombin G20210A mutation",
"   </p>",
"   <p>",
"    This analysis also determined the additional risk posed by the use of oral contraceptives in women aged 15 to 49 in the three case-control studies in which this information was available. The risk of VTE was increased two- to six-fold in subjects with one \"defect\", 7- to 15-fold in those with two defects, and 17-fold in those using oral contraceptives with both genetic defects (ie, all three \"defects\").",
"   </p>",
"   <p>",
"    In a retrospective study of first degree relatives from selected thrombophilic families (ie, at least two symptomatic relatives in addition to the proband), factor VIII levels &ge;150 international",
"    <span class=\"nowrap\">",
"     units/dL",
"    </span>",
"    increased the risk of thrombosis threefold in carriers of factor V Leiden [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/44\">",
"     44",
"    </a>",
"    ]. In first degree relatives of unselected patients with factor V Leiden (ie, relatives of consecutive patients with a first thrombosis), high levels of factor VIII increased the thrombotic risk of carriers twofold.",
"   </p>",
"   <p>",
"    The risk of thrombosis was also increased in patients with factor V Leiden and hyperhomocysteinemia. In a large prospective cohort study, the relative risk for idiopathic VTE compared with patients with neither abnormality was 3.4 with hyperhomocysteinemia, 3.6 with the factor V Leiden mutation, and 21.8 with both disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2406396\">",
"    <span class=\"h3\">",
"     Risk of recurrent DVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data as to whether the factor V Leiden mutation is, or is not, associated with an increased risk of recurrent venous thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/72,86-88\">",
"     72,86-88",
"    </a>",
"    ], with odds ratios varying from 0.90 to 3.62 for 10 studies included in one meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/89\">",
"     89",
"    </a>",
"    ]. Examples of this diversity of opinion include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two series, patients with factor V Leiden who had a first venous thrombotic event were more than twice as likely to have a recurrent episode than those without the mutation at follow-ups ranging from 5.7 to 8 years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/72,86,90\">",
"       72,86,90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Six studies found no difference in the incidence of recurrence between those with and without factor V Leiden [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/87,91-95\">",
"       87,91-95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Three different meta-analyses have reported an odds of VTE recurrence associated with factor V Leiden of 1.30, 1.36, and 1.41 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/89,96,97\">",
"       89,96,97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In four studies, the risk of recurrence was increased in patients heterozygous for factor V Leiden who were also heterozygous for the prothrombin gene mutation or a concomitant thrombophilic disorder, particularly those in whom the first episode of DVT was spontaneous (see below) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/91,94,98\">",
"       91,94,98",
"      </a>",
"      ]. However, a case-control study within a large thrombophilic family cohort did not find a higher recurrence risk in those with combined inherited defects [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/99\">",
"       99",
"      </a>",
"      ]. Although the number of events were small and the confidence limits wide, individuals with homozygous factor V Leiden",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      homozygous prothrombin G20210A or those doubly heterozygous for factor V Leiden and prothrombin G20210A did not appear to have a higher risk of recurrent VTE than noncarriers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reports are also conflicting as to whether the risk of VTE recurrence in patients with factor V Leiden is [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/100,101\">",
"     100,101",
"    </a>",
"    ] or is not [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/102\">",
"     102",
"    </a>",
"    ] increased over noncarriers in those receiving anticoagulation for a shorter period of time (eg, &lt;3 months versus &gt;6 months).",
"   </p>",
"   <p>",
"    While these different results are likely due to somewhat different patient populations and more importantly different study population sizes, it can be concluded that heterozygosity for factor V Leiden is only a modest risk factor for a first episode of DVT and is most likely not associated with an increased risk for recurrent DVT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H31#H31\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Recurrent VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further, in a follow-up study of 396 patients with a first episode of VTE, the risk of VTE recurrence in those who were heterozygous for factor V Leiden and also had high levels of factors VIII, IX, or XI was not increased over the risk in those without factor V Leiden who had normal levels of these three coagulation factors (crude hazard ratio 1.4; 95% CI 0.6-3.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Acquired risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an important interaction between factor V Leiden and other acquired risk factors for venous thrombosis (eg, oral contraceptives, hormone replacement therapy, pregnancy) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/104-113\">",
"     104-113",
"    </a>",
"    ]. The magnitude of the increase in risk can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    In 155 consecutive premenopausal women with deep vein thrombosis, the risk among those with both oral contraceptive use and the factor V Leiden mutation was increased more than 30-fold compared with women with neither risk factor; the increase in risk was lower (four- to eightfold) with either risk factor alone (",
"    <a class=\"graphic graphic_table graphicRef56252 \" href=\"UTD.htm?21/4/21579\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second study has provided data that might explain the increased risk for venous thrombosis in oral contraceptives users and the interaction with factor V Leiden [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/114\">",
"     114",
"    </a>",
"    ]. In this report, the effects of activated protein C on thrombin generation in the plasma of women using oral contraceptives were compared to the response in women not using oral contraceptives and in women heterozygous or homozygous for the factor V Leiden mutation. Oral contraceptives induced a degree of activated protein C resistance comparable with the resistance caused by a heterozygous factor V Leiden mutation. In women heterozygous for factor V Leiden who used oral contraceptives, the degree of activated protein C resistance was as high as that among women homozygous for the factor V Leiden mutation.",
"   </p>",
"   <p>",
"    The risk of venous thromboembolic disease associated with the various forms of oral contraceptives is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H11#H11\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Venous thromboembolic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A long-term study of 9253 randomly selected Danish patients found increasing risk for venous thromboembolism (VTE) with age, smoking, increasing body mass index (BMI), and presence of factor V Leiden [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/115\">",
"     115",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H52#H52\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Obesity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H53#H53\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Smoking'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absolute 10-year risks for VTE were 0.7 and 3 percent among heterozygotes and homozygotes, respectively, who were &lt;40 years of age, did not smoke, and were not overweight.",
"     </li>",
"     <li>",
"      The 10-year risks for VTE in heterozygotes and homozygotes &gt;60 years of age who smoked and were overweight (body mass index &gt;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      were 10 and 51 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear whether the factor V Leiden mutation increases the risk of thrombosis in patients with malignancy or following insertion of central venous catheters. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H4#H4\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Venous thromboembolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Obstetric complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetric complications and treatment during pregnancy in patients with factor V Leiden are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Isolated pulmonary emboli",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing isolated pulmonary emboli (ie, without concomitant deep vein thrombosis) in patients with factor V Leiden has been reported to be about one-half (odds ratio 2.5) that of the risk of developing deep vein thrombosis with (odds ratio 5.2) or without (odds ratio 6.0) pulmonary emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/116-119\">",
"     116-119",
"    </a>",
"    ]. The cause of this interesting &ldquo;Factor V Leiden paradox&rdquo; is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/117,120,121\">",
"     117,120,121",
"    </a>",
"    ], but may be due to the lower incidence in patients with factor V Leiden of deep vein thrombi affecting the large, proximal iliofemoral vessels most often associated with the generation of symptomatic pulmonary emboli.",
"   </p>",
"   <p>",
"    In one study, the incidence of severe dyspnea was significantly higher in 20 factor V Leiden homozygotes (32 percent) than in 699 heterozygotes or 8534 non-carriers (7 and 6 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/122\">",
"     122",
"    </a>",
"    ]. Homozygotes also had evidence for reduced pulmonary function. The explanation for these differences is not known, but may reflect continuing subclinical episodes of recurrent pulmonary embolism in the homozygotes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cerebral vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factor V Leiden mutation occurs with increased frequency in patients with cerebral vein thrombosis (CVT) (10 to 20 percent versus 2 to 3 percent in controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/123-125\">",
"     123-125",
"    </a>",
"    ]. As with deep vein thrombosis, CVT occurs more frequently in young women who are taking oral contraceptives or who are pregnant or in the postpartum state. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of oral contraceptives alone is a strong risk factor for CVT, and the addition of oral contraceptives to the presence of factor V Leiden results in a risk that exceeds the sum of the two separate risks. In a case control study, for example, the estimated odds ratios for CVT were 10 for the use of oral contraceptives, three to four for hereditary prothrombotic disorders, and 34 for the presence of both risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2405808\">",
"    <span class=\"h2\">",
"     Superficial vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study in subjects with superficial vein thrombosis (SVT) as the sole thrombotic manifestation, and in the absence of varicose veins, malignancy, or autoimmune disease, the odds ratio for the development of SVT in those heterozygous for factor V Leiden was 4.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/127\">",
"     127",
"    </a>",
"    ]. Other studies have demonstrated a high prevalence of factor V Leiden in subjects with SVT on normal veins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/128,129\">",
"     128,129",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=see_link&amp;anchor=H8#H8\">",
"     \"Superficial thrombophlebitis of the lower extremity\", section on 'Malignancy and hypercoagulable states'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Arterial thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between factor V Leiden and arterial disease remains controversial, although there appears to be a weak but significant association between premature myocardial infarction (ie, first event before age 45) and factor V Leiden [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/130,131\">",
"     130,131",
"    </a>",
"    ]. There are a number of studies, including two meta-analyses, which have generally been unable to find an increased prevalence of the mutation in patients with myocardial infarction (MI) and stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/73,132-137\">",
"     73,132-137",
"    </a>",
"    ]. However, it is not clear whether there is a small risk that is amplified considerably when there are additional coronary risk factors present (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28217?source=see_link\">",
"     \"Coronary heart disease and myocardial infarction in young men and women\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case control study in patients &le;60 years of age with ischemic",
"      <span class=\"nowrap\">",
"       stroke/transient",
"      </span>",
"      ischemic attack, an increase in stroke risk was confined to female smokers with factor V Leiden (odds ratio 8.8 95% CI 2.0-38) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/138\">",
"       138",
"      </a>",
"      ]. No such interaction was found for men.",
"     </li>",
"     <li>",
"      In a case control study in young women (18 to 44 years of age), the factor V Leiden mutation was associated with a 2.4-fold increase in risk of MI after adjustment for age; this increase in risk was limited to current smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/139\">",
"       139",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third study, factor V Leiden was found in 12 percent of young patients (mean age 44 years) with MI and normal coronary angiography, in 4.5 percent of age- and sex-matched patients with MI and significant coronary artery disease, and 5 percent of normal controls [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/140\">",
"       140",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a fourth report, presence of eight prothrombotic gene polymorphisms, including factor V Leiden, was not associated with an increased or decreased risk of premature MI [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/141\">",
"       141",
"      </a>",
"      ]. However, a later publication from this group, which included more cases, found a significant association between factor V Leiden and premature MI [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/131\">",
"       131",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factor V Leiden may be a more important contributor to cerebral infarction in children than in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/137\">",
"     137",
"    </a>",
"    ]. In one series of 26 such children, factor V Leiden was present in six; two of these children also had protein C deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Settings in which thrombotic risk may not be increased",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data as to whether the factor V Leiden mutation increases the underlying thrombotic risk in patients who are undergoing hip or knee replacement therapy or have pulmonary emboli, who more frequently have preexisting medical illness, or have undergone recent surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/143-145\">",
"     143-145",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study of 825 patients undergoing hip or knee replacement surgery was unable to demonstrate an increased risk of venographically documented events postoperatively among patients with the factor V Leiden mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/143\">",
"       143",
"      </a>",
"      ]. The absolute incidence of deep vein thrombosis was 31 percent in patients with the mutation and 26 percent in those without the mutation.",
"     </li>",
"     <li>",
"      A prospective study of 645 consecutive patients undergoing elective hip or knee replacement found a fivefold increase (95 percent confidence interval: 1.9 to 12.9) in the risk of symptomatic postoperative VTE in patients with, as compared with those without, APC resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/145\">",
"       145",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC ASSAYS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     First generation APC resistance assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activated partial thromboplastin time (aPTT)-based assays serve as a screening test for APC resistance. The aPTT is performed in the presence and absence of a standardized amount of APC, and the two clotting times are converted to an APC ratio. The results can be interpreted by comparing the ratio to the normal range or by normalizing it to the APC resistance ratio obtained using normal pooled plasma.",
"   </p>",
"   <p>",
"    Although this first generation APC resistance assay was conceptually simple and easy to perform in a coagulation laboratory, it required careful standardization and determination of the normal range in at least 50 controls. In addition, the level of activated protein C, the aPTT reagent, and the instrumentation used for clot detection affected the performance characteristics of the assay.",
"   </p>",
"   <p>",
"    Some assays using this format had inadequate sensitivity and specificity for the factor V Leiden mutation. Further, patients receiving anticoagulants or those with an abnormal aPTT due to other coagulation defects could not be investigated with this assay, and the test was not validated in patients with acute thrombotic events or pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Second generation APC resistance assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second generation coagulation tests have been developed which, with proper standardization, can give nearly 100 percent sensitivity and 100 percent specificity for the factor V Leiden mutation. This was achieved by diluting patient plasma in a sufficient volume of factor V-deficient plasma and then performing either an aPTT-based assay or a tissue factor-dependent factor V assay [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/147,148\">",
"     147,148",
"    </a>",
"    ]. This modification also permits the evaluation of plasma of patients receiving anticoagulants or with abnormal aPTT results due to coagulation factor deficiencies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since factor V Leiden is the major mutation underlying APC resistance, this defect can be detected directly by analyzing genomic DNA in peripheral blood mononuclear cells. This is performed by amplifying a DNA fragment containing the factor V mutation site by polymerase chain reaction (PCR) and analyzing the cleavage products on ethidium bromide-stained agarose gels after restriction enzyme digestion with MnlI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/5\">",
"     5",
"    </a>",
"    ]. This approach is effective because the substitution of an A for a G at nucleotide 1691 in the factor V cDNA (CGA to CAA) results in the Arg506Gln mutation and loss of an MnlI cleavage site.",
"   </p>",
"   <p>",
"    Other approaches using PCR with sequence-specific primers or capture probes or direct detection of the mutation without amplification have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/35/28218/abstract/149,150\">",
"     149,150",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, the factor V Leiden mutation can be identified by testing for APC resistance using a second generation coagulation assay. Patients with low APC resistance ratios should then be genotyped for the mutation. Alternatively, only genetic testing for the factor V Leiden mutation can be performed.",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=see_link\">",
"       \"Patient information: Factor V Leiden (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Activated protein C resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein C, which is converted to activated protein C, along with protein S, are natural anticoagulants that are produced within the body. Their anticoagulant activity comes about through the enzymatic degradation of factors VIIIa and Va. Resistance to this effect of activated protein C is called activated protein C resistance (APC resistance).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heterozygosity for the factor V Leiden mutation (factor V Q506, Arg506Gln) accounts for 90 to 95 percent of cases of",
"      <strong>",
"       hereditary",
"      </strong>",
"      APC resistance.",
"     </li>",
"     <li>",
"      The most common causes of",
"      <strong>",
"       acquired",
"      </strong>",
"      APC resistance include elevated factor VIII levels, pregnancy, use of oral contraceptives, and the presence of antiphospholipid antibodies. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Acquired APC resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Factor V Leiden",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activated form of Factor V Leiden is not susceptible to cleavage at position 506 by activated protein C and is therefore inactivated more slowly. It is the most common cause of inherited thrombophilia in Caucasian populations, accounting for 40 to 50 percent of cases. Its incidence in most European studies is about 5 to 8 percent. The mutation is not present in African Blacks, Chinese, or Japanese populations. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Physiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Nature of the hypercoagulable state",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor V Leiden is associated with a",
"    <span class=\"nowrap\">",
"     prothrombotic/thrombophilic",
"    </span>",
"    state through two different mechanisms. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Physiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of hemostasis\", section on 'Multicomponent complexes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased coagulation &mdash; The activated form of Factor V Leiden is inactivated more slowly by APC than is normal Factor Va. Accordingly, more factor Va is available within the prothrombinase complex, increasing coagulation via the increased generation of thrombin.",
"     </li>",
"     <li>",
"      Decreased anticoagulation &mdash; Factor V cleaved at position 506 is a cofactor, along with protein S, in supporting the role of activated protein C in the degradation of factors VIIIa and Va. Lack of this cleavage product decreases the anticoagulant activity of activated protein C.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This hypercoagulable state can be exacerbated when a patient heterozygous for factor V Leiden has one or more",
"    <strong>",
"     additional",
"    </strong>",
"    causes for hypercoagulability (eg, heterozygosity for the prothrombin gene mutation, use of oral contraceptives).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Diagnosing factor V Leiden",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most direct way to diagnose factor V Leiden is through genetic testing, although second generation APC resistance assays can give nearly 100 percent sensitivity and 100 percent specificity for the factor V Leiden mutation. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Diagnostic assays'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Screening for the factor V Leiden mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for the Factor V Leiden mutation in patients with venous thromboembolic disease, their relatives, and in the population at large is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Screening for inherited thrombophilia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Management of the patient with factor V Leiden",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of the patient with heterozygous factor V Leiden, double heterozygosity for factor V Leiden and another inherited thrombophilia, or homozygous factor V Leiden is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of inherited thrombophilia\", section on 'Factor V Leiden'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link&amp;anchor=H6#H6\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\", section on 'Homozygosity and multiple defects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link&amp;anchor=H7898363#H7898363\">",
"     \"Inherited thrombophilias in pregnancy\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/1\">",
"      Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/2\">",
"      Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G--&gt;A20210 gene variant. Ann Intern Med 1998; 129:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/3\">",
"      Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. J Thromb Haemost 2010; 8:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/4\">",
"      Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270:4053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/5\">",
"      Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/6\">",
"      Nicolaes GA, Dahlb&auml;ck B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol 2002; 22:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/7\">",
"      Thorelli E, Kaufman RJ, Dahlb&auml;ck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999; 93:2552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/8\">",
"      Castoldi E, Brugge JM, Nicolaes GA, et al. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004; 103:4173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/9\">",
"      Cramer TJ, Gale AJ. The anticoagulant function of coagulation factor V. Thromb Haemost 2012; 107:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/10\">",
"      Dahlback B. Anticoagulant factor V and thrombosis risk (editorial). Blood 2004; 103:3995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/11\">",
"      Simioni P, Castoldi E, Lunghi B, et al. An underestimated combination of opposites resulting in enhanced thrombotic tendency. Blood 2005; 106:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/12\">",
"      Z&ouml;ller B, Svensson PJ, He X, Dahlb&auml;ck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/13\">",
"      de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/14\">",
"      Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/15\">",
"      Lee DH, Henderson PA, Blajchman MA. Prevalence of factor V Leiden in a Canadian blood donor population. CMAJ 1996; 155:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/16\">",
"      Awidi A, Shannak M, Bseiso A, et al. High prevalence of factor V Leiden in healthy Jordanian Arabs. Thromb Haemost 1999; 81:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/17\">",
"      Irani-Hakime N, Tamim H, Kreidy R, Almawi WY. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol 2000; 65:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/18\">",
"      Taher A, Khalil I, Shamseddine A, et al. High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation? Thromb Haemost 2001; 86:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/19\">",
"      Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/20\">",
"      Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997; 89:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/21\">",
"      Zivelin A, Rosenberg N, Faier S, et al. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood 1998; 92:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/22\">",
"      Williamson D, Brown K, Luddington R, et al. Factor V Cambridge: a new mutation (Arg306--&gt;Thr) associated with resistance to activated protein C. Blood 1998; 91:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/23\">",
"      Chan WP, Lee CK, Kwong YL, et al. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/24\">",
"      Liang R, Lee CK, Wat MS, et al. Clinical significance of Arg306 mutations of factor V gene. Blood 1998; 92:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/25\">",
"      Steen M, Norstr&oslash;m EA, Tholander AL, et al. Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis. Blood 2004; 103:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/26\">",
"      Mingozzi F, Legnani C, Lunghi B, et al. A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers. Thromb Haemost 2003; 89:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/27\">",
"      Bernardi F, Faioni EM, Castoldi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/28\">",
"      Alhenc-Gelas M, Nicaud V, Gandrille S, et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999; 81:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/29\">",
"      Margaglione M, Bossone A, Coalizzo D, et al. FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a high-risk profile. Thromb Haemost 2002; 87:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/30\">",
"      Luddington R, Jackson A, Pannerselvam S, et al. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost 2000; 83:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/31\">",
"      Benson JM, Ellingsen D, El-Jamil M, et al. Factor V Leiden and factor V R2 allele: high-throughput analysis and association with venous thromboembolism. Thromb Haemost 2001; 86:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/32\">",
"      Faioni EM, Franchi F, Bucciarelli P, et al. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999; 94:3062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/33\">",
"      Folsom AR, Cushman M, Tsai MY, et al. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood 2002; 99:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/34\">",
"      Tormene D, Fortuna S, Tognin G, et al. The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort study. J Thromb Haemost 2005; 3:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/35\">",
"      Reitsma PH, Bernardi F, Doig RG, et al. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 73:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/36\">",
"      Simioni P, Scudeller A, Radossi P, et al. \"Pseudo homozygous\" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost 1996; 75:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/37\">",
"      Zehnder JL, Jain M. Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency. Blood Coagul Fibrinolysis 1996; 7:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/38\">",
"      Guasch JF, Lensen RP, Bertina RM. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is \"pseudo homozygous\" for activated protein C resistance. Thromb Haemost 1997; 77:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/39\">",
"      Brugge JM, Simioni P, Bernardi F, et al. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. J Thromb Haemost 2005; 3:2695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/40\">",
"      Duckers C, Simioni P, Tormene D, et al. Factor V Leiden pseudo-homozygotes have a more pronounced hypercoagulable state than factor V Leiden homozygotes. J Thromb Haemost 2011; 9:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/41\">",
"      Robert A, Aillaud MF, Eschw&egrave;ge V, et al. ABO blood group and risk of venous thrombosis in heterozygous carriers of factor V Leiden. Thromb Haemost 2000; 83:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/42\">",
"      Morelli VM, De Visser MC, Vos HL, et al. ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost 2005; 3:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/43\">",
"      Procare-GEHT Group. ABO blood group but not haemostasis genetic polymorphisms significantly influence thrombotic risk: a study of 180 homozygotes for the Factor V Leiden mutation. Br J Haematol 2006; 135:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/44\">",
"      Lensen R, Bertina RM, Vandenbroucke JP, Rosendaal FR. High factor VIII levels contribute to the thrombotic risk in families with factor V Leiden. Br J Haematol 2001; 114:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/45\">",
"      Morange PE, Tregouet DA, Frere C, et al. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Br J Haematol 2005; 128:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/46\">",
"      Segers O, Simioni P, Tormene D, et al. Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. J Thromb Haemost 2012; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/47\">",
"      Fisher M, Fernandez JA, Ameriso SF, et al. Activated protein C resistance in ischemic stroke not due to factor V arginine506--&gt;glutamine mutation. Stroke 1996; 27:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/48\">",
"      van der Bom JG, Bots ML, Haverkate F, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996; 125:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/49\">",
"      Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/50\">",
"      Haim N, Lanir N, Hoffman R, et al. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001; 110:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/51\">",
"      Nijziel MR, van Oerle R, Christella M, et al. Acquired resistance to activated protein C in breast cancer patients. Br J Haematol 2003; 120:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/52\">",
"      Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/53\">",
"      Elice F, Fink L, Tricot G, et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/54\">",
"      Clark P, Walker ID. The phenomenon known as acquired activated protein C resistance. Br J Haematol 2001; 115:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/55\">",
"      Tosetto A, Simioni M, Madeo D, Rodeghiero F. Intraindividual consistency of the activated protein C resistance phenotype. Br J Haematol 2004; 126:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/56\">",
"      Curvers J, Thomassen MC, Rimmer J, et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002; 88:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/57\">",
"      Post MS, Rosing J, Van Der Mooren MJ, et al. Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. Br J Haematol 2002; 119:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/58\">",
"      Legnani C, Cini M, Cosmi B, et al. Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis. Thromb Haemost 2004; 91:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/59\">",
"      Stolz E, Kemkes-Matthes B, P&ouml;tzsch B, et al. Screening for thrombophilic risk factors among 25 German patients with cerebral venous thrombosis. Acta Neurol Scand 2000; 102:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/60\">",
"      A��ao��lu N, Mustafa NA, T&uuml;rkyilmaz S. Prothrombotic disorders in patients with mesenteric vein thrombosis. J Invest Surg 2003; 16:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/61\">",
"      El-Karaksy H, El-Koofy N, El-Hawary M, et al. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. Ann Hematol 2004; 83:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/62\">",
"      Heijmans BT, Westendorp RG, Knook DL, et al. The risk of mortality and the factor V Leiden mutation in a population-based cohort. Thromb Haemost 1998; 80:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/63\">",
"      Ridker PM, Miletich JP, Buring JE, et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/64\">",
"      Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/65\">",
"      Tormene D, Simioni P, Prandoni P, et al. The risk of fetal loss in family members of probands with factor V Leiden mutation. Thromb Haemost 1999; 82:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/66\">",
"      Martinelli I, Taioli E, Cetin I, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/67\">",
"      Middeldorp S, Meinardi JR, Koopman MM, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 135:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/68\">",
"      Svensson PJ, Dahlb&auml;ck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/69\">",
"      Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/70\">",
"      Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/71\">",
"      Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/72\">",
"      Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506--&gt;Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/73\">",
"      Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/74\">",
"      Lensen RP, Rosendaal FR, Koster T, et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 1996; 88:4205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/75\">",
"      Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/76\">",
"      Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/77\">",
"      Gandrille S, Greengard JS, Alhenc-Gelas M, et al. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM. Blood 1995; 86:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/78\">",
"      Koeleman BP, van Rumpt D, Hamuly&aacute;k K, et al. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995; 74:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/79\">",
"      Z&ouml;ller B, Berntsdotter A, Garc&iacute;a de Frutos P, Dahlb&auml;ck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85:3518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/80\">",
"      van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/81\">",
"      Ehrenforth S, Ludwig G, Klinke S, et al. The prothrombin 20210 A allele is frequently coinherited in young carriers of the factor V Arg 506 to Gln mutation with venous thrombophilia. Blood 1998; 91:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/82\">",
"      Tosetto A, Rodeghiero F, Martinelli I, et al. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation. Br J Haematol 1998; 103:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/83\">",
"      Koeleman BP, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol 1997; 34:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/84\">",
"      Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/85\">",
"      Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/86\">",
"      Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92:2800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/87\">",
"      Eichinger S, Pabinger I, St&uuml;mpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/88\">",
"      Keijzer MB, den Heijer M, Blom HJ, et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002; 88:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/89\">",
"      Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/90\">",
"      Simioni P, Prandoni P, Lensing AW, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 2000; 96:3329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/91\">",
"      De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/92\">",
"      Lindmarker P, Schulman S, Sten-Linder M, et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999; 81:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/93\">",
"      Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/94\">",
"      Margaglione M, D'Andrea G, Colaizzo D, et al. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999; 82:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/95\">",
"      Eichinger S, Weltermann A, Mannhalter C, et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 2002; 162:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/96\">",
"      Vink R, Kraaijenhagen RA, Levi M, B&uuml;ller HR. Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model. J Thromb Haemost 2003; 1:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/97\">",
"      Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis. Thromb Haemost 2000; 84:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/98\">",
"      Meinardi JR, Middeldorp S, de Kam PJ, et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol 2002; 116:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/99\">",
"      Lijfering WM, Middeldorp S, Veeger NJ, et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation 2010; 121:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/100\">",
"      Santamaria MG, Agnelli G, Taliani MR, et al. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res 2005; 116:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/101\">",
"      Prandoni P, Tormene D, Spiezia L, et al. Duration of anticoagulation and risk of recurrent thromboembolism in carriers of factor V Leiden or prothrombin mutation. J Thromb Haemost 2008; 6:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/102\">",
"      Schulman S, Lindmarker P. Thrombophilic polymorphism--a short-term or long-term risk for recurrence? J Thromb Haemost 2008; 6:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/103\">",
"      Lijfering WM, Christiansen SC, Rosendaal FR, Cannegieter SC. Contribution of high factor VIII, IX and XI to the risk of recurrent venous thrombosis in factor V Leiden carriers. J Thromb Haemost 2009; 7:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/104\">",
"      Vandenbroucke JP, Koster T, Bri&euml;t E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/105\">",
"      Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, Vandenbroucke JP. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost 1997; 78:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/106\">",
"      Hellgren M, Svensson PJ, Dahlb&auml;ck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/107\">",
"      Hirsch DR, Mikkola KM, Marks PW, et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996; 131:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/108\">",
"      Rosendaal FR, Vessey M, Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/109\">",
"      Herrington DM, Vittinghoff E, Howard TD, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002; 22:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/110\">",
"      Bokarewa MI, Bremme K, Blomb&auml;ck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/111\">",
"      McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/112\">",
"      Dizon-Townson DS, Nelson LM, Jang H, et al. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am J Obstet Gynecol 1997; 176:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/113\">",
"      Lensen RP, Bertina RM, de Ronde H, et al. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 2000; 83:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/114\">",
"      Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/115\">",
"      Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 2004; 140:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/116\">",
"      de Moerloose P, Reber G, Perrier A, et al. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol 2000; 110:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/117\">",
"      Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism. Lancet 2000; 356:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/118\">",
"      Meyer G, Emmerich J, Helley D, et al. Factors V leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis. Am J Med 2001; 110:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/119\">",
"      M&auml;kelburg AB, Veeger NJ, Middeldorp S, et al. Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. Haematologica 2010; 95:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/120\">",
"      Bj&ouml;rgell O, Nilsson PE, Nilsson JA, Svensson PJ. Location and extent of deep vein thrombosis in patients with and without FV:R 506Q mutation. Thromb Haemost 2000; 83:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/121\">",
"      van Langevelde K, Flinterman LE, van Hylckama Vlieg A, et al. Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum. Blood 2012; 120:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/122\">",
"      Juul K, Tybjaerg-Hansen A, Mortensen J, et al. Factor V leiden homozygosity, dyspnea, and reduced pulmonary function. Arch Intern Med 2005; 165:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/123\">",
"      Zuber M, Toulon P, Marnet L, Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. Stroke 1996; 27:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/124\">",
"      L&uuml;demann P, Nabavi DG, Junker R, et al. Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients. Stroke 1998; 29:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/125\">",
"      Deschiens MA, Conard J, Horellou MH, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996; 27:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/126\">",
"      de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ 1998; 316:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/127\">",
"      Martinelli I, Cattaneo M, Taioli E, et al. Genetic risk factors for superficial vein thrombosis. Thromb Haemost 1999; 82:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/128\">",
"      Gillet JL, Allaert FA, Perrin M. [Superficial thrombophlebitis in non varicose veins of the lower limbs. A prospective analysis in 42 patients]. J Mal Vasc 2004; 29:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/129\">",
"      Milio G, Siragusa S, Min&agrave; C, et al. Superficial venous thrombosis: prevalence of common genetic risk factors and their role on spreading to deep veins. Thromb Res 2008; 123:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/130\">",
"      Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/131\">",
"      Mannucci PM, Asselta R, Duga S, et al. The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease. J Thromb Haemost 2010; 8:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/132\">",
"      Demarmels Biasiutti F, Merlo C, Furlan M, et al. No association of APC resistance with myocardial infarction. Blood Coagul Fibrinolysis 1995; 6:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/133\">",
"      Kontula K, Ylikorkala A, Miettinen H, et al. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/134\">",
"      Longstreth WT Jr, Rosendaal FR, Siscovick DS, et al. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998; 29:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/135\">",
"      Cushman M, Rosendaal FR, Psaty BM, et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998; 79:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/136\">",
"      Dunn ST, Roberts CR, Schechter E, et al. Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease. Thromb Res 1998; 91:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/137\">",
"      Juul K, Tybjaerg-Hansen A, Steffensen R, et al. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002; 100:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/138\">",
"      Lalouschek W, Schillinger M, Hsieh K, et al. Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke 2005; 36:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/139\">",
"      Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/140\">",
"      Mansourati J, Da Costa A, Munier S, et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000; 83:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/141\">",
"      Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/142\">",
"      Becker S, Heller C, Gropp F, et al. Thrombophilic disorders in children with cerebral infarction. Lancet 1998; 352:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/143\">",
"      Ryan DH, Crowther MA, Ginsberg JS, Francis CW. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med 1998; 128:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/144\">",
"      Desmarais S, de Moerloose P, Reber G, et al. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996; 347:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/145\">",
"      Lindahl TL, Lundahl TH, Nilsson L, Andersson CA. APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee--a prospective study. Thromb Haemost 1999; 81:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/146\">",
"      Zehnder JL, Benson RC. Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden. Am J Clin Pathol 1996; 106:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/147\">",
"      Le DT, Griffin JH, Greengard JS, et al. Use of a generally applicable tissue factor--dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 1995; 85:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/148\">",
"      Dahlb&auml;ck B. Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995; 73:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/149\">",
"      Zehnder JL, Benson RC, Cheng S. A microplate allele-specific oligonucleotide hybridization assay for detection of factor V Leiden. Diagn Mol Pathol 1997; 6:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/35/28218/abstract/150\">",
"      Zehnder J, Van Atta R, Jones C, et al. Cross-linking hybridization assay for direct detection of factor V Leiden mutation. Clin Chem 1997; 43:1703.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1355 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28218=[""].join("\n");
var outline_f27_35_28218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dual defect leading to hypercoagulable state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CAUSES AND PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Heterozygosity for factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Homozygosity for factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other genetic defects in factor V",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - HR2 haplotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Factor V Leiden plus factor V deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other genetic influences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Acquired APC resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Risk of DVT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Combined inherited defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2406396\">",
"      - Risk of recurrent DVT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Acquired risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Obstetric complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Isolated pulmonary emboli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cerebral vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2405808\">",
"      Superficial vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Arterial thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Settings in which thrombotic risk may not be increased",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DIAGNOSTIC ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      First generation APC resistance assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Second generation APC resistance assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Activated protein C resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Nature of the hypercoagulable state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Diagnosing factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Screening for the factor V Leiden mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Management of the patient with factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1355\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1355|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/4/21579\" title=\"table 1\">",
"      Risk factors VTE genetic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=related_link\">",
"      Biology and normal function of von Willebrand factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28217?source=related_link\">",
"      Coronary heart disease and myocardial infarction in young men and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=related_link\">",
"      Patient information: Factor V Leiden (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=related_link\">",
"      Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=related_link\">",
"      Superficial thrombophlebitis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/32/20999?source=related_link\">",
"      Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_35_28219="Indications for TIPS";
var content_f27_35_28219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for placement of transjugular intrahepatic portosystemic shunts*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\" rowspan=\"1\">",
"        Accepted indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active hemorrhage despite emergent endoscopic treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent variceal hemorrhage despite adequate endoscopic treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other potential indications- efficacy proven but not adequately compared to existing modalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding isolated varices in gastric fundus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refractory ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Experimental indications- efficacy not well established by large-scale published trials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding portal hypertensive gastropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Budd-Chiari syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic veno-occlusive disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatorenal syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic hydrothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding ectopic varices",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein-losing enteropathy due to portal hypertension",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Only accepted indications should be used for routine clinical practice.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28219=[""].join("\n");
var outline_f27_35_28219=null;
var title_f27_35_28220="Integration GAPS routine care";
var content_f27_35_28220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Steps for successful integration of comprehensive adolescent preventive services into routine medical care",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        1. Conduct a needs assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        How many adolescent patients are seen in the practice?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - What are their ages?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - What are their problems?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        What are the current preventive service practice patterns of the practitioners?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        2. Determine clinic readiness to make a systems change",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Are adolescent preventive services an important aspect of care for the staff and the clinic?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Are adequate resources available, such as health education materials and questionnaires?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Are the administrators supportive of change?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        3. Identify a staff prevention coordinator and specify roles and responsibilities:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Setting goals for the implementation process",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coordinating implementation activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Establishing a tracking system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ensuring new staff are trained",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conducting quality assurance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        4. Identify a set of preventive services guidelines to be used by the clinic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        5. Develop clinic procedures and protocols to address the following issues:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        How will privacy and confidentiality be handled?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        How will screening questionnaires be used?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Who will provide health guidance? Health risk reduction counseling?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        6. Provide staff training and preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        7. Identify and promote mechanisms to maximize reimbursement for preventive services",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Appropriate use of Current Procedural Terminology (CPT) codes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        8. Establish school and community referral sources",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28220=[""].join("\n");
var outline_f27_35_28220=null;
var title_f27_35_28221="Distal response to furosemide";
var content_f27_35_28221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Loop diuretic-induced increase in distal tubule sodium reabsorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 292px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diuretic responsiveness in patients previously treated with placebo or the loop diuretic furosemide. The subjects who had been treated with furosemide had a lesser increase in the fractional excretion of sodium (FENa) after the administration of furosemide (left panel), but a greater natriuretic response to the addition of chlorothiazide (right panel). These findings are compatible with increased tubular sodium reabsorption at the thiazide-sensitive site in the distal tubule when distal sodium delivery is chronically increased by furosemide.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Loon NR, Wilcox CS, Unwin RJ. Kidney Int 1989; 36:682.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28221=[""].join("\n");
var outline_f27_35_28221=null;
var title_f27_35_28222="Contents: Headache";
var content_f27_35_28222=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/63/1022\">",
"       Neurology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Headache",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Headache",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cluster headache and other trigeminal autonomic cephalalgias",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/51/3898\">",
"           Cluster headache: Acute and preventive treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/63/14327\">",
"           Cluster headache: Epidemiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/60/25545\">",
"           Paroxysmal hemicrania: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/57/9112\">",
"           Paroxysmal hemicrania: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/34/27174\">",
"           Pathophysiology of the trigeminal autonomic cephalalgias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28648\">",
"           SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/13/2264\">",
"           SUNCT and SUNA headache syndromes: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cranial neuralgias and central causes of facial pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/8/32904\">",
"           Central craniofacial pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/23/31090\">",
"           Cold stimulus headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/48/6917\">",
"           Nervus intermedius (geniculate) neuralgia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/55/16243\">",
"           Nummular headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/49/31509\">",
"           Occipital neuralgia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/10/11431\">",
"           Overview of craniofacial pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/3/34873\">",
"           Trigeminal neuralgia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation and treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/51/34615\">",
"           Evaluation of headache in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/49/39704\">",
"           Evaluation of the adult with headache in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/63/5114\">",
"           Headache in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Migraine",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/44/21194\">",
"           Acute treatment of migraine in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/44/44743\">",
"           Basilar-type migraine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/61/7128\">",
"           Chronic migraine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/38/35433\">",
"           Estrogen-associated migraine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32953\">",
"           Headache, migraine, and stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/60/17354\">",
"           Hemiplegic migraine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/8/15496\">",
"           Migrainous vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/4/26698\">",
"           Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/56/42889\">",
"           Preventive treatment of migraine in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nonvascular intracranial disorder",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/43/41655\">",
"           Brain tumor headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/15/27894\">",
"           Syndrome of transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis (HaNDL)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other primary headaches",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/34/3624\">",
"           Headache syndromes other than migraine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/58/43942\">",
"           Hemicrania continua",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/36/5700\">",
"           Hypnic headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/2/35879\">",
"           Medication overuse headache: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/48/17161\">",
"           Medication overuse headache: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/57/2968\">",
"           New daily persistent headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/60/37830\">",
"           Overview of chronic daily headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/37/22101\">",
"           Primary cough headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/20/44356\">",
"           Primary exertional headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/43/16054\">",
"           Primary headache associated with sexual activity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/25/13714\">",
"           Primary stabbing headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/19/12601\">",
"           Thunderclap headache",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Secondary headaches",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/43/41655\">",
"           Brain tumor headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/60/26568\">",
"           Cervicogenic headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/20/330\">",
"           Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/46/20198\">",
"           Post-lumbar puncture headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13126\">",
"           Treatment and prognosis of spontaneous low cerebrospinal fluid pressure headache",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tension-type headache",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/13/37079\">",
"           Tension-type headache in adults: Acute treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/43/32441\">",
"           Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/25/1433\">",
"           Tension-type headache in adults: Preventive treatment",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-B3CD223586-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_35_28222=[""].join("\n");
var outline_f27_35_28222=null;
var title_f27_35_28223="Zollinger-Ellison syndrome algorithm";
var content_f27_35_28223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Zollinger-Ellison syndrome algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 615px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ZES: Zollinger-Ellison syndrome; PUD: peptic ulcer disease; PPI: proton pump inhibitor; EUS: endoscopic ultrasound; MRI: magnetic resonance imaging; Liver mets: liver metastases.",
"     <br/>",
"     * Upper limit of normal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_35_28223=[""].join("\n");
var outline_f27_35_28223=null;
